US20130004484A1 - Anti-c-met antibody formulations - Google Patents

Anti-c-met antibody formulations Download PDF

Info

Publication number: US20130004484A1
Authority: US; United States
Prior art keywords: antibody; pharmaceutical formulation; met; sequence; seq
Prior art date: 2011-06-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

US13/538,901

Other languages

English (en)

Inventor

Barthelemy Demeule

Bruce Kabakoff

Jun Liu

Nicole Piros

Qing Zhu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

F Hoffmann La Roche AG

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-30

Filing date

2012-06-29

Publication date

2013-01-03

2012-06-29 Application filed by Genentech Inc filed Critical Genentech Inc

2012-06-29 Priority to US13/538,901 priority Critical patent/US20130004484A1/en

2012-08-30 Assigned to GENENTECH, INC. reassignment GENENTECH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KABAKOFF, BRUCE, PIROS, Nicole, DEMEULE, Barthelemy, LIN, JUN, ZHU, QING

2012-10-04 Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GENENTECH, INC.

2013-01-03 Publication of US20130004484A1 publication Critical patent/US20130004484A1/en

2014-11-05 Priority to US14/534,085 priority patent/US9487589B2/en

Status Abandoned legal-status Critical Current

Links

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

compositions comprising an anti-c-met antibody and uses of the same.
Excipients are added to pharmaceutical formulations to aid in the stabilization of the active compound.
the compatibility of the excipients with the active compound is crucial for the quality and stability of the pharmaceutical formulation. While excipients are important in the stabilization of the active compound, excipients can cause problems: the excipient may degrade and thus lose its mechanism of stabilization or it may produce degradants that interact with the active compound.
compositions in which the active compound is a polypeptide can pose special problems as polypeptides generally are larger and more complex than traditional organic and inorganic molecules (for example, polypeptides possess multiple functional groups, in addition to complex three-dimensional structures).
polypeptides possess multiple functional groups, in addition to complex three-dimensional structures.
the pharmaceutical polypeptide formulation must preserve intact the conformational integrity of at least a core sequence of the polypeptide's amino acids, while at the same time maintaining physical and chemical stability of the pharmaceutical polypeptide formulation.
Excipients are generally stable in aqueous solution; however, excipients in a pharmaceutical polypeptide formulation can interact with the polypeptide to undergo degradation in a formulation and can prevent the stabilization of the protein or the degradants could interact with the polypeptide to pose challenges (such as a loss in activity). Therefore, the evaluation of the interaction of the non-active components of the pharmaceutical formulation and polypeptide active agent is crucial for ensuring chemical and physical stability.
Polysorbates are non-ionic surfactants used to stabilize an active compound against interface induced aggregation and surface adsorption. Polysorbates can be effective against various stresses such as agitation (for example, shaking or stirring), freeze/thawing, and lyophilization. In pharmaceutical polypeptide formulations, polysorbates minimize adsorption to surfaces and reduce the air-liquid interfacial surface tension and thus the rate of protein denaturation. Loss of polysorbate in the pharmaceutical formulation can result in instability of the formulation. Further, polysorbates can be degraded by oxidation and hydrolysis which can lead to a decrease in the apparent concentration of polysorbate in the pharmaceutical formulation over long shelf life.
Polysorbates e.g., polysorbate 20
degradants e.g., free lauric acid and sorbitan polyoxyethylene side chain.
These polysorbate degradants are less surface-active than nondegraded polysorbate and hence the chemical and physical stability of the pharmaceutical formulation may be compromised.
some polysorbate degradants are insoluble and may form particles if they are not solubilized by intact polysorbate, i.e., if the ratio of degraded polysorbate 20: intact polysorbate 20 is too high.
the rate and extent of degradation of polysorbate is influenced by the chemical and physical properties of the active compound, and the stabilizing ability of polysorbate can vary between different pharmaceutical formulations comprising different active compounds.
the stabilizing ability of polysorbate can vary between different pharmaceutical formulations comprising different active compounds.
polysorbates are included in protein formulations to stabilize the protein, the decrease in the concentration of polysorbate and the accumulation of degradant molecules in a pharmaceutical polypeptide formulation is of potential concern for protein stability.
c-met and anti-c-met antibodies include a portion of the extracellular domain of c-met and anti-c-met antibodies such as those described in U.S. Pat. No. 5,686,292, Martens, T. et al., Clin. Cancer Res. 12 (20 Pt. 1):6144 (2006); U.S. Pat. No. 6,468,529; WO2006/015371; WO2007/063816, and WO2010/045345.
Bivalent forms of anti-c-met antibodies have been shown to promote dimerization and lead to activation of c-met (agonistic function), while conversely monovalent antibodies have been shown to inhibit c-met activity (antagonistic function).
Fab fragments and one-armed antibodies are examples of monovalent antibodies.
One-armed antibodies generally have a longer half-life than Fabs.
the polypeptides could potentially form a bivalent antibody with two heavy chain and two light chains.
compositions comprising an anti-c-met antibody.
the pharmaceutical formulation is a liquid pharmaceutical formulation.
the pharmaceutical formulation is a stable pharmaceutical formulation.
the pharmaceutical formulation is a stable liquid pharmaceutical formulation.
the anti-c-met antibody is an antagonist anti-c-met antibody.
compositions comprising: (a) an anti-c-met antibody; (b) a histidine buffer at pH 5.0-5.4; (c) a saccharide; and (d) a polysorbate, wherein the polysorbate is present at greater than 0.02% w/v.
the anti-c-met antibody comprising a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6).
the anti-c-met antibody comprises (a) a heavy chain variable domain comprising the sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRF NPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS (SEQ ID NO:19) and (b) a light chain variable domain comprising the sequence: DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTR ESGVPSRFSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKR (SEQ ID NO:20).
the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.
the first and second Fc polypeptides form a Fc region that increases stability of said antibody fragment compared to a Fab molecule comprising said antigen binding arm.
the anti-c-met antibody comprises (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO:19, a CH1 sequence, and a first Fc polypeptide and (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO:20 and CL1 sequence.
the anti-c-met antibody further comprises (c) a third polypeptide comprising a second Fc polypeptide.
the first Fc polypeptide comprises the Fc sequence depicted in FIG. 2 (SEQ ID NO: 17) and the second Fc polypeptide comprises the Fc sequence depicted in FIG. 3 (SEQ ID NO: 18).
the anti-c-met antibody is onartuzumab. In some embodiments, the anti-c-met antibody binds the same epitope as onartuzumab.
the anti-c-met antibody is present at a concentration between about 10 mg/mL and about 100 mg/mL (e.g. about 15 mg/mL and about 75 mg/mL). In some embodiments, the anti-c-met antibody is present at a concentration of about 60 mg/mL.
the saccharide is present at a concentration of about 75 mM to about 200 mM (e.g., about 100 mM to about 150 mM). In some embodiments, the saccharide is present at a concentration of about 120 mM. In some embodiments, the saccharide is a disaccharide. In some embodiments, the disaccharide is trehalose. In some embodiments, the disaccharide is sucrose.
the histidine buffer is at a concentration of about 1 mM to about 50 mM (e.g. about 1 mM to about 25 mM). In some embodiments, the histidine buffer is at a concentration of about 10 mM. In some embodiments, the histidine buffer is histidine acetate.
the polysorbate is present at a concentration greater than 0.02% and less than about 0.1%. In some embodiments, the polysorbate is present at a concentration of about 0.04%. In some embodiments, the polysorbate is polysorbate 20.
the formulation is diluted with a diluent (e.g., 0.9% NaCl).
a diluent e.g. 0.9% NaCl
the anti-c-met antibody is present at a concentration of about 1 mg/mL.
c-met activated cell proliferation comprising contacting a cell or tissue with an effective amount of the pharmaceutical formulation described herein (e.g., upon dilution).
the methods comprising administering to the subject an effective amount of the pharmaceutical formulation described herein (e.g., upon dilution).
the proliferative disorder is cancer.
the cancer is lung cancer (non-small cell lung cancer (NSCLC)), glioblastoma, pancreatic cancer, sarcoma, renal cell carcinoma, hepatocellular carcinoma, gastric cancer, colorectal cancer, and/or breast cancer.
the methods further comprise a second therapeutic agent.
articles of manufacture comprising a container with a pharmaceutical formulation described herein (e.g., upon dilution) contained therein.
methods of making the articles of manufacture comprising a pharmaceutical formulation described herein (e.g., upon dilution).
FIG. 1 depicts the general structures of short half-life and long half-life agonists and antagonists of c-Met.
FIG. 2 depicts amino acid sequences of the framework (FR), hypervariable region (HVR), first constant domain (CL or CH1) and Fc region (Fc) of MetMAb (onartuzumab or OA5D5.v2).
the Fc sequence depicted comprises “hole” (cavity) mutations T366S, L368A and Y407V, as described in WO 2005/063816.
FIG. 3 depicts sequence of an Fc polypeptide comprising “knob” (protuberance) mutation T366W, as described in WO 2005/063816.
an Fc polypeptide comprising this sequence forms a complex with an Fc polypeptide comprising the Fc sequence of FIG. 1 to generate an Fc region.
the sequence disclosed in FIG. 3 represents residues 6-227 of SEQ ID NO: 18.
FIG. 4 depicts the rate of aggregate formation as indicated by the percentage of high molecular weight species (HMWS) over time (days) at 40° C. for formulations of 20 mg/mL onartuzumab, 10 mM histidine acetate, 120 mM trehalose, and 0.02% polysorbate 20 at pH 5.2, 5.7, and 6.2.
HMWS high molecular weight species
FIG. 5 depicts the rate of aggregate formation as indicated by the percentage of high molecular weight species (HMWS) over time (days) at 25° C. for formulations of 40 mg/mL onartuzumab, 10 mM histidine acetate, 120 mM trehalose, and 0.02% polysorbate 20 at pH 5.1, 5.4, and 5.7.
HMWS high molecular weight species
FIG. 6 depicts the rate of aggregate formation as indicated by the percentage of high molecular weight species (HMWS) over time (days) at 40° C. for formulations of 40 mg/mL onartuzumab, 10 mM histidine acetate, 120 mM trehalose, and 0.02% polysorbate 20 at pH 5.1, 5.4, and 5.7.
HMWS high molecular weight species
FIG. 7 depicts the chemical stability as measured by ion-exchange chromatography (IEC) as indicated by the percent main peak over time (days) at 25° C. and 40° C. for formulations of 40 mg/mL onartuzumab, 10 mM histidine acetate, 120 mM trehalose, and 0.02% polysorbate 20 at pH 5.1, 5.4, and 5.7.
IEC ion-exchange chromatography
FIG. 8 depicts the percentage of intact polysorbate over time (weeks) at 40° C. for formulations of 60 mg/mL onartuzumab, 10 mM histidine acetate, pH 5.4, and 120 mM sucrose with 0.02% polysorbate 20 or 0.04% polysorbate 20.
FIG. 9 depicts the rate of aggregate formation of onartuzumab diluted to 1 mg/mL in IV bags containing 0.9% NaCl.
the rate of aggregation is indicated by the percentage of high molecular weight species (HMWS) over time (hours) of agitation for diluted formulations of (a) 60 mg/mL onartuzumab, 10 mM histidine acetate, 120 mM trehalose, and 0.02% polysorbate 20 at pH 5.4 kept at room temperature as shown by squares and (b) 60 mg/mL onartuzumab, 10 mM histidine acetate, 120 mM sucrose, and 0.04% polysorbate 20 at pH 5.4 kept at 30° C. as shown by circles.
HMWS high molecular weight species
stable pharmaceutical formulations comprising an anti-c-met antibody.
the anti-c-met antibody is an antagonist anti-c-met antibody.
the anti-c-met antibody is a monovalent anti-c-met antibody.
kits and articles of manufacture comprising the anti-c-met antibody pharmaceutical formulations and uses of the anti-c-met antibody pharmaceutical formulations are provided.
pharmaceutical formulation refers to preparations which are in such form as to permit the biological activity of the active compound(s) to be effective, and which contain no additional components which are toxic to the subjects to which the formulation is administered.
“Pharmaceutically acceptable” excipients are those which can reasonably be administered to a subject to provide an effective dose of the active compound.
a “stable” formulation is one in which the polypeptide therein essentially retains its physical stability and/or chemical stability and/or biological activity upon storage and/or during administration (e.g., after dilution in an IV bag).
Various analytical techniques for measuring protein stability are available in the art and are reviewed in Peptide and Protein Drug Delivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, N.Y., Pubs. (1991) and Jones, A. Adv. Drug Delivery Rev. 10: 29-90 (1993), for example. Stability can be measured at a selected temperature for a selected time period.
a polypeptide “retains its chemical stability” in a pharmaceutical formulation if the chemical stability at a given time is such that the protein is considered to still retain its biological activity.
Chemical stability can be assessed by detecting and quantifying chemically altered forms of the protein.
Chemical alteration may involve size modification (e.g., clipping) which can be evaluated using size exclusion chromatography, SDS-PAGE and/or matrix-assisted laser desorption ionization/time-of-flight mass spectrometry (MALDI/TOF MS), for example.
Other types of chemical alteration include charge alteration which can be evaluated by ion-exchange chromatography, for example.
a “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject.
a pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
a “histidine buffer” is a buffer comprising histidine ions.
a “saccharide” herein comprises the general composition (CH 2 O) n and derivatives thereof.
an “anti-c-met antibody” and “an antibody that binds to c-met” refer to an antibody that is capable of binding c-met with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting c-met.
the extent of binding of an anti-c-met antibody to an unrelated, non-c-met protein is less than about 10% of the binding of the antibody to c-met as measured, e.g., by a radioimmunoassay (RIA).
an antibody that binds to c-met has a dissociation constant (Kd) of ⁇ 1 ⁇ M, ⁇ 100 nM, ⁇ 10 nM, ⁇ 1 nM, ⁇ 0.1 nM, ⁇ 0.01 nM, or ⁇ 0.001 nM (e.g., 10 ⁇ 8 M or less, e.g. from 10 ⁇ 8 M to 10 ⁇ 13 M, e.g., from 10 ⁇ 9 M to 10 ⁇ 13 M).
Kd dissociation constant
an anti-c-met antibody binds to an epitope of c-met that is conserved among c-met from different species.
antibody is used in the broadest sense and specifically covers monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), monovalent antibodies, multivalent antibodies, and antibody fragments so long as they exhibit the desired biological activity (e.g., Fab and/or single-armed antibodies).
the “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain.
the heavy chain constant domains that correspond to the different classes of immunoglobulins are called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
antibody fragment refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds.
antibody fragments include but are not limited to Fv, Fab, Fab′, Fab′-SH, F(ab′) 2 ; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.
full length antibody “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
a “blocking” antibody or an “antagonist” antibody is one which significantly inhibits (either partially or completely) a biological activity of the antigen it binds.
an “antibody that binds to the same epitope” as a reference antibody refers to an antibody that blocks binding of the reference antibody to its antigen in a competition assay by 50% or more, and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by 50% or more.
An exemplary competition assay is provided herein.
acceptor human framework for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below.
An acceptor human framework “derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less.
the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.
variable region refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen.
the variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs).
FRs conserved framework regions
HVRs hypervariable regions
antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).
hypervariable region refers to each of the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops (“hypervariable loops”).
native four-chain antibodies comprise six HVRs; three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3).
HVRs generally comprise amino acid residues from the hypervariable loops and/or from the “complementarity determining regions” (CDRs), the latter being of highest sequence variability and/or involved in antigen recognition.
CDRs complementarity determining regions
Exemplary hypervariable loops occur at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3).
Exemplary CDRs CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 occur at amino acid residues 24-34 of L1, 50-56 of L2, 89-97 of L3, 31-35B of H1, 50-65 of H2, and 95-102 of H3.
CDRs generally comprise the amino acid residues that form the hypervariable loops.
CDRs also comprise “specificity determining residues,” or “SDRs,” which are residues that contact antigen. SDRs are contained within regions of the CDRs called abbreviated-CDRs, or a-CDRs.
Exemplary a-CDRs (a-CDR-L1, a-CDR-L2, a-CDR-L3, a-CDR-H1, a-CDR-H2, and a-CDR-H3) occur at amino acid residues 31-34 of L1, 50-55 of L2, 89-96 of L3, 31-35B of H1, 50-58 of H2, and 95-102 of H3.
HVR residues and other residues in the variable domain are numbered herein according to Kabat et al., supra.
“Framework” or “FR” refers to variable domain residues other than hypervariable region (HVR) residues.
the FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
N-terminally truncated heavy chain refers to a polypeptide comprising parts but not all of a full length immunoglobulin heavy chain, wherein the missing parts are those normally located on the N terminal region of the heavy chain. Missing parts may include, but are not limited to, the variable domain, CH1, and part or all of a hinge sequence. Generally, if the wild type hinge sequence is not present, the remaining constant domain(s) in the N-terminally truncated heavy chain would comprise a component that is capable of linkage to another Fc sequence (i.e., the “first” Fc polypeptide as described herein). For example, said component can be a modified residue or an added cysteine residue capable of forming a disulfide linkage.
Fc region generally refers to a dimer complex comprising the C-terminal polypeptide sequences of an immunoglobulin heavy chain, wherein a C-terminal polypeptide sequence is that which is obtainable by papain digestion of an intact antibody.
the Fc region may comprise native or variant Fc sequences.
the boundaries of the Fc sequence of an immunoglobulin heavy chain may vary, the human IgG heavy chain Fc sequence is usually defined to stretch from an amino acid residue at about position Cys226, or from about position Pro230, to the carboxyl-terminus of the Fc sequence.
the C-terminal lysine (Lys447) of the Fc sequence may or may not be present.
the Fc sequence of an immunoglobulin generally comprises two constant domains, a CH2 domain and a CH3 domain, and optionally comprises a CH4 domain.
Fc polypeptide herein is meant one of the polypeptides that make up an Fc region.
An Fc polypeptide may be obtained from any suitable immunoglobulin, such as IgG1, IgG2, IgG3, or IgG4 subtypes, IgA, IgE, IgD or IgM.
an Fc polypeptide comprises part or all of a wild type hinge sequence (generally at its N terminus). In some embodiments, an Fc polypeptide does not comprise a functional or wild type hinge sequence.
Fc receptor or “FcR” describes a receptor that binds to the Fc region of an antibody.
an FcR is a native human FcR.
an FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the Fc ⁇ RI, Fc ⁇ RII, and Fc ⁇ RIII subclasses, including allelic variants and alternatively spliced forms of those receptors.
Fc ⁇ RII receptors include Fc ⁇ RIIA (an “activating receptor”) and Fc ⁇ RIIB (an “inhibiting receptor”), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof.
Activating receptor Fc ⁇ RIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain
Inhibiting receptor Fc ⁇ RIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain.
ITAM immunoreceptor tyrosine-based activation motif
ITIM immunoreceptor tyrosine-based inhibition motif
Fc receptor or “FcR” also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)) and regulation of homeostasis of immunoglobulins. Methods of measuring binding to FcRn are known (see, e.g., Ghetie and Ward., Immunol. Today 18(12):592-598 (1997); Ghetie et al., Nature Biotechnology, 15(7):637-640 (1997); Hinton et al., J. Biol. Chem. 279(8):6213-6216 (2004); WO 2004/92219 (Hinton et al.).
Binding to human FcRn in vivo and serum half life of human FcRn high affinity binding polypeptides can be assayed, e.g., in transgenic mice or transfected human cell lines expressing human FcRn, or in primates to which the polypeptides with a variant Fc region are administered.
WO 2000/42072 (Presta) describes antibody variants with improved or diminished binding to FcRs. See also, e.g., Shields et al. J. Biol. Chem. 9(2):6591-6604 (2001).
the “hinge region,” “hinge sequence”, and variations thereof, as used herein, includes the meaning known in the art, which is illustrated in, for example, Janeway et al., Immuno Biology: the immune system in health and disease, (Elsevier Science Ltd., NY) (4th ed., 1999); Bloom et al., Protein Science (1997), 6:407-415; Humphreys et al., J. Immunol. Methods (1997), 209:193-202.
multivalent antibody is used throughout this specification to denote an antibody comprising three or more antigen binding sites.
the multivalent antibody is preferably engineered to have the three or more antigen binding sites and is generally not a native sequence IgM or IgA antibody.
an “Fv” fragment is an antibody fragment which contains a complete antigen recognition and binding site. This region consists of a dimer of one heavy and one light chain variable domain in tight association, which can be covalent in nature, for example in scFv. It is in this configuration that the three HVRs of each variable domain interact to define an antigen binding site on the surface of the V H -V L dimer. Collectively, the six HVRs or a subset thereof confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three HVRs specific for an antigen) has the ability to recognize and bind antigen, although usually at a lower affinity than the entire binding site.
the “Fab” fragment contains a variable and constant domain of the light chain and a variable domain and the first constant domain (CH1) of the heavy chain.
F(ab′) 2 antibody fragments comprise a pair of Fab fragments which are generally covalently linked near their carboxy termini by hinge cysteines between them. Other chemical couplings of antibody fragments are also known in the art.
antigen binding arm refers to a component part of an antibody fragment that has an ability to specifically bind a target molecule of interest.
the antigen binding arm is a complex of immunoglobulin polypeptide sequences, e.g., HVR and/or variable domain sequences of an immunoglobulin light and heavy chain.
Single-chain Fv or “scFv” antibody fragments comprise the V H and V L domains of antibody, wherein these domains are present in a single polypeptide chain.
the Fv polypeptide further comprises a polypeptide linker between the V H and V L domains, which enables the scFv to form the desired structure for antigen binding.
diabodies refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy chain variable domain (V H ) connected to a light chain variable domain (V L ) in the same polypeptide chain (V H and V L ).
V H heavy chain variable domain
V L light chain variable domain
linear antibodies refers to the antibodies described in Zapata et al., Protein Eng., 8(10):1057-1062 (1995). Briefly, these antibodies comprise a pair of tandem Fd segments (V H -C H 1-V H -C H 1) which, together with complementary light chain polypeptides, form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.
the term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts.
polyclonal antibody preparations typically include different antibodies directed against different determinants (epitopes)
each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen.
the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
the monoclonal antibodies to be used may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.
chimeric antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.
a “human consensus framework” is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences.
the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences.
the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest , Fifth Edition, NIH Publication 91-3242, Bethesda Md. (1991), vols. 1-3.
the subgroup is subgroup kappa I as in Kabat et al., supra.
the subgroup is subgroup III as in Kabat et al., supra.
a “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs.
a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody.
a humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody.
a “humanized form” of an antibody, e.g., a non-human antibody refers to an antibody that has undergone humanization.
a “human antibody” is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.
naked antibody refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel.
the naked antibody may be present in a pharmaceutical formulation.
“Native antibodies” refer to naturally occurring immunoglobulin molecules with varying structures.
native IgG antibodies are heterotetrameric glycoproteins of about 150,000 Daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain.
VH variable region
VL variable region
the light chain of an antibody may be assigned to one of two types, called kappa ( ⁇ ) and lambda ( ⁇ ), based on the amino acid sequence of its constant domain.
Bind refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen).
binding affinity refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen).
the affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described in the following.
an “affinity matured” antibody refers to an antibody with one or more alterations in one or more HVRs, compared to a parent antibody which does not possess such alterations, such alterations resulting in an improvement in the affinity of the antibody for antigen.
An antibody having a “biological characteristic” of a designated antibody is one which possesses one or more of the biological characteristics of that antibody which distinguish it from other antibodies that bind to the same antigen.
a “functional antigen binding site” of an antibody is one which is capable of binding a target antigen.
the antigen binding affinity of the antigen binding site is not necessarily as strong as the parent antibody from which the antigen binding site is derived, but the ability to bind antigen must be measurable using any one of a variety of methods known for evaluating antibody binding to an antigen.
the antigen binding affinity of each of the antigen binding sites of a multivalent antibody herein need not be quantitatively the same.
the number of functional antigen binding sites can be evaluated using ultracentrifugation analysis as described in Example 2 of U.S. Patent Application Publication No. 20050186208.
a “species-dependent antibody” is one which has a stronger binding affinity for an antigen from a first mammalian species than it has for a homologue of that antigen from a second mammalian species.
the species-dependent antibody “binds specifically” to a human antigen (i.e. has a binding affinity (K d ) value of no more than about 1 ⁇ 10 ⁇ 7 M, preferably no more than about 1 ⁇ 10 ⁇ 8 M and most preferably no more than about 1 ⁇ 10 ⁇ 9 M) but has a binding affinity for a homologue of the antigen from a second nonhuman mammalian species which is at least about 50 fold, or at least about 500 fold, or at least about 1000 fold, weaker than its binding affinity for the human antigen.
the species-dependent antibody can be any of the various types of antibodies as defined above. In some embodiments, the species-dependent antibody is a humanized or human antibody.
an “isolated” antibody is one which has been separated from a component of its natural environment.
an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC).
electrophoretic e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis
chromatographic e.g., ion exchange or reverse phase HPLC
substantially similar refers to a sufficiently high degree of similarity between two numeric values (for example, one associated with an antibody and the other associated with a reference/comparator antibody), such that one of skill in the art would consider the difference between the two values to be of little or no biological and/or statistical significance within the context of the biological characteristic measured by said values (e.g., Kd values).
substantially reduced refers to a sufficiently high degree of difference between two numeric values (generally one associated with a molecule and the other associated with a reference/comparator molecule) such that one of skill in the art would consider the difference between the two values to be of statistical significance within the context of the biological characteristic measured by said values (e.g., Kd values).
“Effector functions” refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor); and B cell activation.
an “immunoconjugate” is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.
cytotoxic agent refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction.
Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212 and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof; and
a “disorder” is any condition that would benefit from treatment with a substance/molecule or method described herein. This includes chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question.
disorders to be treated herein include malignant and benign tumors; non-leukemias and lymphoid malignancies; neuronal, glial, astrocytal, hypothalamic and other glandular, macrophagal, epithelial, stromal and blastocoelic disorders; and inflammatory, immunologic and other angiogenesis-related disorders.
cell proliferative disorder and “proliferative disorder” refer to disorders that are associated with some degree of abnormal cell proliferation.
the cell proliferative disorder is cancer.
Tumor refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
cancer refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
cancer refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells
cancer and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth/proliferation.
examples of cancer include, but are not limited to, carcinoma, lymphoma (e.g., Hodgkin's and non-Hodgkin's lymphoma), blastoma, sarcoma, and leukemia.
cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, leukemia and other lymphoproliferative disorders, and various types of head and neck cancer.
the cancer is triple-negative (ER-, PR-, HER2-) cancer.
the cancer is triple-negative metastatic breast cancer, including any histologically confirmed triple-negative (ER-, PR-, HER2-) adenocarcinoma of the breast with locally recurrent or metastatic disease, e.g., where the locally recurrent disease is not amenable to resection with curative intent.
Metastasis is meant the spread of cancer from its primary site to other places in the body. Cancer cells can break away from a primary tumor, penetrate into lymphatic and blood vessels, circulate through the bloodstream, and grow in a distant focus (metastasize) in normal tissues elsewhere in the body. Metastasis can be local or distant. Metastasis is a sequential process, contingent on tumor cells breaking off from the primary tumor, traveling through the bloodstream, and stopping at a distant site. At the new site, the cells establish a blood supply and can grow to form a life-threatening mass. Both stimulatory and inhibitory molecular pathways within the tumor cell regulate this behavior, and interactions between the tumor cell and host cells in the distant site are also significant.
treatment refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.
antibodies are used to delay development of a disease or to slow the progression of a disease.
an “effective amount” of an agent refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
a “therapeutically effective amount” refers to an amount of a therapeutic agent to treat or prevent a disease or disorder in a mammal.
the therapeutically effective amount of the therapeutic agent may reduce the number of cancer cells; reduce the primary tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the disorder.
the drug may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic.
efficacy in vivo can, for example, be measured by assessing the duration of survival, time to disease progression (TTP), the response rates (RR), duration of response, and/or quality of life.
mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats).
domesticated animals e.g., cows, sheep, cats, dogs, and horses
primates e.g., humans and non-human primates such as monkeys
rabbits e.g., mice and rats
rodents e.g., mice and rats.
the individual or subject is a human.
anti-cancer therapy refers to a therapy useful in treating cancer.
anti-cancer therapeutic agents include, but are limited to, e.g., chemotherapeutic agents, growth inhibitory agents, cytotoxic agents, agents used in radiation therapy, anti-angiogenesis agents, apoptotic agents, anti-tubulin agents, and other agents to treat cancer, anti-CD20 antibodies, platelet derived growth factor inhibitors (e.g., GleevecTM (Imatinib Mesylate)), a COX-2 inhibitor (e.g., celecoxib), interferons, cytokines, antagonists (e.g., neutralizing antibodies) that bind to one or more of the following targets PDGFR-beta, BlyS, APRIL, BCMA receptor(s), TRAIL/Apo2, and other bioactive and organic chemical agents, etc. Combinations thereof are also included.
cytotoxic agent refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells.
the term is intended to include radioactive isotopes (e.g., At 211 , I 131 , I 125 , Y 90 , Re 186 , Re188, sm 153 , Bi 212 , P 32 and radioactive isotopes of Lu), chemotherapeutic agents e.g.
methotrexate adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents, enzymes and fragments thereof such as nucleolytic enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof, and the various antitumor or anticancer agents disclosed below. Other cytotoxic agents are described below.
a tumoricidal agent causes destruction of tumor cells.
chemotherapeutic agent refers to a chemical compound useful in the treatment of cancer.
examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclosphosphamide (CYTOXAN®); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylomelamine; acetogenins (especially bullatacin and bullatacinone); delta-9-tetrahydrocannabinol (dronabinol, MARINOL®); beta-lapachone; lapachol; colchicines; betulinic acid; a camptothecin (including the synthetic analogue topotecan (HYCAMTIN®
celecoxib or etoricoxib proteosome inhibitor
proteosome inhibitor e.g., PS341
bortezomib VELCADE®
CCI-779 tipifarnib (R11577); orafenib, ABT510
Bcl-2 inhibitor such as oblimersen sodium (GENASENSE®)
pixantrone EGFR inhibitors (see definition below); tyrosine kinase inhibitors (see definition below); serine-threonine kinase inhibitors such as rapamycin (sirolimus, RAPAMUNE®); farnesyltransferase inhibitors such as lonafarnib (SCH 6636, SARASARTM); and pharmaceutically acceptable salts, acids or derivatives of any of the above; as well as combinations of two or more of the above such as CHOP, an abbreviation for a combined therapy of cyclophosphamide, doxorubicin, vincris
Chemotherapeutic agents as defined herein include “anti-hormonal agents” or “endocrine therapeutics” which act to regulate, reduce, block, or inhibit the effects of hormones that can promote the growth of cancer. They may be hormones themselves, including, but not limited to: anti-estrogens with mixed agonist/antagonist profile, including, tamoxifen (NOLVADEX®), 4-hydroxytamoxifen, toremifene (FARESTON®), idoxifene, droloxifene, raloxifene (EVISTA®), trioxifene, keoxifene, and selective estrogen receptor modulators (SERMs) such as SERM3; pure anti-estrogens without agonist properties, such as fulvestrant (FASLODEX®), and EM800 (such agents may block estrogen receptor (ER) dimerization, inhibit DNA binding, increase ER turnover, and/or suppress ER levels); aromatase inhibitors, including steroidal aromatase inhibitors such as forme
prodrug refers to a precursor or derivative form of a pharmaceutically active substance that is less cytotoxic to tumor cells compared to the parent drug and is capable of being enzymatically activated or converted into the more active parent form. See, e.g., Wilman, “Prodrugs in Cancer Chemotherapy” Biochemical Society Transactions, 14, pp. 375-382, 615th Meeting Harbor (1986) and Stella et al., “Prodrugs: A Chemical Approach to Targeted Drug Delivery,” Directed Drug Delivery , Borchardt et al., (ed.), pp. 247-267, Humana Press (1985).
the prodrugs include, but are not limited to, phosphate-containing prodrugs, thiophosphate-containing prodrugs, sulfate-containing prodrugs, peptide-containing prodrugs, D-amino acid-modified prodrugs, glycosylated prodrugs, ⁇ -lactam-containing prodrugs, optionally substituted phenoxyacetamide-containing prodrugs or optionally substituted phenylacetamide-containing prodrugs, 5-fluorocytosine and other 5-fluorouridine prodrugs which can be converted into the more active cytotoxic free drug.
cytotoxic drugs that can be derivatized into a prodrug form for use include, but are not limited to, those chemotherapeutic agents described above.
a “growth inhibitory agent” when used herein refers to a compound or composition which inhibits growth of a cell (e.g., a cell whose growth is dependent upon HGF/c-met activation either in vitro or in vivo).
the growth inhibitory agent may be one which significantly reduces the percentage of HGF/c-met-dependent cells in S phase.
growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest.
Classical M-phase blockers include the vincas (vincristine and vinblastine), taxanes, and topoisomerase II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin.
Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C.
Taxanes are anticancer drugs both derived from the yew tree.
Docetaxel (TAXOTERE®, Rhone-Poulenc Rorer), derived from the European yew, is a semisynthetic analogue of paclitaxel (TAXOL®, Bristol-Myers Squibb). Paclitaxel and docetaxel promote the assembly of microtubules from tubulin dimers and stabilize microtubules by preventing depolymerization, which results in the inhibition of mitosis in cells.
radiation therapy is meant the use of directed gamma rays or beta rays to induce sufficient damage to a cell so as to limit its ability to function normally or to destroy the cell altogether. It will be appreciated that there will be many ways known in the art to determine the dosage and duration of treatment. Typical treatments are given as a one time administration and typical dosages range from 10 to 200 units (Grays) per day.
concurrent administration includes a dosing regimen when the administration of one or more agent(s) continues after discontinuing the administration of one or more other agent(s).
Reduce or inhibit is meant the ability to cause an overall decrease of 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or greater. Reduce or inhibit can refer to the symptoms of the disorder being treated, the presence or size of metastases, or the size of the primary tumor.
package insert is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.
the pharmaceutical formulation is a liquid pharmaceutical formulation.
the pharmaceutical formulation is a stable pharmaceutical formulation.
the pharmaceutical formulation is a stable liquid pharmaceutical formulation.
the anti-c-met antibody is an antagonist anti-c-met antibody.
the anti-c-met antibody is a monovalent anti-c-met antibody. Minimization in the pharmaceutical formulation of anti-c-met antibody aggregation is particularly important. Bivalent forms of anti-c-met antibodies have been shown to promote dimerization and lead to activation of c-met (agonistic function), while conversely monovalent antibodies inhibit c-met activity (antagonistic function). Aggregation of monovalent antibodies (formation of multimer and oligomers) and/or failure to maintain monovalent structure in a pharmaceutical formulation comprising anti-c-met antibodies could lead to an undesirable agonistic effect.
compositions comprising (a) an anti-c-met antibody and (b) a polysorbate, wherein the polysorbate concentration is greater than 0.02% w/v.
the pharmaceutical formulation comprises (a) an anti-c-met antibody; (b) a polysorbate, wherein the polysorbate concentration is greater than 0.02% w/v; and (c) a histidine buffer (e.g., a histidine buffer at a pH between 5.0 and 5.4).
the pharmaceutical formulation comprises (a) an anti-c-met antibody; (b) a histidine buffer at pH 5.0-5.4; (c) a saccharide; and (d) a polysorbate, wherein the polysorbate concentration is greater than 0.02% w/v.
the pharmaceutical formulation is a liquid pharmaceutical formulation.
the pharmaceutical formulation is a stable pharmaceutical formulation.
the pharmaceutical formulation is a stable liquid pharmaceutical formulation.
Anti-c-met antibodies useful in the pharmaceutical formulations are described in Section III.
the anti-c-met antibody is an antagonist anti-c-met antibody.
the anti-c-met antibody is a monovalent anti-c-met antibody.
the anti-c-met antibody comprises a single antigen binding arm.
the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, wherein the first and second Fc polypeptides are present in a complex.
the first and second Fc polypeptides form a Fc region that increases stability of said antibody fragment compared to a Fab molecule comprising said antigen binding arm.
the anti-c-met antibody comprises a HVR-L1 comprising the amino acid sequence of SEQ ID NO:1, a HVR-L2 comprising the amino acid sequence of SEQ ID NO:2, a HVR-L3 comprising the amino acid sequence of SEQ ID NO:3, a HVR-H1 comprising the amino acid sequence of SEQ ID NO:4, a HVR-H2 comprising the amino acid sequence of SEQ ID NO:5, and a HVR-H3 comprising the amino acid sequence of SEQ ID NO:6.
the anti-c-met antibody comprises (a) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:19 and (b) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:20.
the anti-c-met antibody comprises (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO:19, a CH1 sequence, and a first Fc polypeptide, (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO:20 and CL1 sequence, and (c) a third polypeptide comprising a second Fc polypeptide.
the first Fc polypeptide comprises the Fc sequence depicted in FIG. 2 (SEQ ID NO: 17) and the second Fc polypeptide comprises the Fc sequence depicted in FIG. 3 (SEQ ID NO: 18).
the anti-c-met antibody is onartuzumab.
the anti-c-met antibody of the pharmaceutical formulation is present at a concentration between about 10 mg/mL and about 100 mg/mL.
the concentration of the anti-c-met antibody e.g., onartuzumab
the concentration of the anti-c-met antibody is between about any of 10 mg/mL to 50 mg/mL, 10 mg/mL to 75 mg/mL, 25 mg/mL to 75 mg/mL, 50 mg/mL to 100 mg/mL, 50 mg/mL to 75 mg/mL, and/or 75 mg/mL to 100 mg/mL.
the concentration of the anti-c-met antibody is greater than about any of 20 mg/mL, 30 mg/mL, 40 mg/mL, 50 mg/mL, 60 mg/mL, 70 mg/mL, or 100 mg/mL.
the pharmaceutical formulation comprises (a) an anti-c-met antibody (e.g., onartuzumab), wherein the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL; (b) a histidine buffer at pH 5.0-5.4; (c) a saccharide; and (d) a polysorbate, wherein the polysorbate concentration is greater than 0.02% w/v.
the concentration of the anti-c-met antibody e.g., onartuzumab
the concentration of the anti-c-met antibody is less than about any of 150 mg/mL, 125 mg/mL, 100 mg/mL, or 75 mg/mL.
the concentration of the anti-c-met antibody is about any of 20 mg/mL, 30 mg/mL, 40 mg/mL, 50 mg/mL, 60 mg/mL, 70 mg/mL, or 80 mg/mL. In some embodiments, the concentration of the anti-c-met antibody (e.g., onartuzumab) is about 60 mg/mL.
the pharmaceutical formulation preferably comprises a polysorbate.
the polysorbate is generally included in an amount which reduces aggregate formation (such as that which occurs upon shaking or shipping).
Examples of polysorbate include, but are not limited to, polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate), and/or polysorbate 80 (polyoxyethylene (20) sorbitan monooleate).
the polysorbate is polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate).
the polysorbate concentration is sufficient to minimize aggregation and/or maintain stability upon long term storage and/or during administration (e.g., after dilution in an IV bag).
the polysorbate concentration is greater than 0.02% w/v, greater than or equal to about 0.03% w/v, or greater than or equal to about 0.04% w/v.
the polysorbate concentration is greater than 0.02% w/v and less than about 0.1% w/v.
the polysorbate concentration is greater than 0.03% w/v and less than about 0.1% w/v.
the polysorbate concentration is about any of 0.03% w/v, 0.04% w/v, or 0.05% w/v. In some embodiments, the polysorbate is present at a concentration of about 0.04% w/v.
the pharmaceutical formulation comprises (a) an anti-c-met antibody (e.g., onartuzumab); (b) a histidine buffer at pH 5.0-5.4; (c) saccharide; and (d) polysorbate 20, wherein the polysorbate 20 concentration is about 0.04% w/v.
the pharmaceutical formulation preferably comprises a saccharide.
Saccharides include monosaccharides, disaccharides, trisaccharides, polysaccharides, sugar alcohols, reducing sugars, nonreducing sugars, etc. Further examples of saccharides include, but are not limited to, glucose, sucrose, trehalose, lactose, fructose, maltose, dextran, glycerin, dextran, erythritol, glycerol, arabitol, sylitol, sorbitol, mannitol, mellibiose, melezitose, raffinose, mannotriose, stachyose, maltose, lactulose, maltulose, glucitol, maltitol, lactitol, iso-maltulose, etc.
the saccharide is a disaccharide. In some embodiments, the saccharide is a nonreducing disaccharide. In some embodiments, the saccharide is trehalose. In some embodiments, the saccharide is sucrose.
the pharmaceutical formulation comprises (a) an anti-c-met antibody (e.g., onartuzumab); (b) a histidine buffer at pH 5.0-5.4; (c) sucrose; and (d) a polysorbate, wherein the polysorbate concentration is greater than 0.02% w/v.
the saccharide is generally included in an amount which reduces aggregate formation.
the saccharide is present at a concentration of between about any of 50 mM to 250 mM, 75 mM to 200 mM, 75 mM to 150 mM, 100 mM to 150 mM, or 110 mM to 130 mM.
the saccharide is present at a concentration greater than about any of 50 mM, 75 mM, 100 mM, 110 mM, or 115 mM.
the saccharide is present at a concentration of about any of 100 mM, 110 mM, 120 mM, 130 mM, or 140 mM.
the saccharide is present at a concentration of about 120 mM.
the pharmaceutical formulation comprises (a) an anti-c-met antibody (e.g., onartuzumab); (b) a histidine buffer at pH 5.0-5.4; (c) sucrose, wherein the sucrose is present at a concentration of about 120 mM; and (d) a polysorbate, wherein the polysorbate concentration is greater than 0.02% w/v.
the pharmaceutical formulation preferably comprises a histidine buffer.
histidine buffers include, but are not limited to, histidine chloride, histidine succinate, histidine acetate, histidine phosphate, histidine sulfate.
the histidine buffer is histidine acetate.
the histidine buffer concentration is between about any of 1 mM to 50 mM, 1 mM to 35 mM, 1 mM to 25 mM, 1 mM to 20 mM, 7.5 mM to 12.5 mM, or 5 mM to 15 mM.
the histidine buffer concentration is greater than or equal to about any of 5 mM, 7.5 mM, or 10 mM. In some embodiments, the histidine buffer concentration is about any of 5 mM, 7.5 mM, 10 mM, 12.5 mM, or 15 mM. In some embodiments, the histidine buffer concentration is about 10 mM. In some embodiments of any of the pharmaceutical formulations described herein, the histidine buffer is at a pH of between pH 5.0 and 5.4, for example, about any of pH 5.0, pH 5.1, pH 5.2, pH 5.3, or pH 5.4. In some embodiments, the pH is between pH 5.1 and 5.4.
the pharmaceutical formulation comprises (a) an anti-c-met antibody (e.g., onartuzumab); (b) a histidine acetate buffer at pH 5.4, wherein the histidine acetate buffer is at a concentration of about 10 mM; (c) saccharide; and (d) a polysorbate, wherein the polysorbate concentration is greater than 0.02% w/v.
an anti-c-met antibody e.g., onartuzumab
the pharmaceutical formulation comprises (a) an anti-c-met antibody (e.g., onartuzumab), wherein the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL; (b) a histidine acetate buffer at pH 5.0-5.4, wherein the histidine acetate buffer is at a concentration between about 1 mM and about 20 mM; (c) sucrose, wherein the sucrose is at a concentration between about 100 mM to about 150 mM; and (d) polysorbate 20, wherein the polysorbate 20 concentration is greater than 0.02% w/v.
an anti-c-met antibody e.g., onartuzumab
the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL
a histidine acetate buffer at pH 5.0-5.4 wherein the histidine acetate buffer is at a concentration between about 1 mM and about 20 mM
the pharmaceutical formulation comprises (a) an anti-c-met antibody (e.g., onartuzumab), wherein the anti-c-met antibody is present at a concentration of about 60 mg/mL; (b) a histidine acetate buffer at pH 5.4, wherein the histidine acetate buffer is at a concentration of about 10 mM; (c) sucrose, wherein the sucrose is at a concentration of about 120 mM; and (d) polysorbate 20, wherein the polysorbate 20 concentration is about 0.04% w/v.
an anti-c-met antibody e.g., onartuzumab
the anti-c-met antibody is present at a concentration of about 60 mg/mL
a histidine acetate buffer at pH 5.4 wherein the histidine acetate buffer is at a concentration of about 10 mM
sucrose wherein the sucrose is at a concentration of about 120 mM
polysorbate 20 concentration is about 0.04% w/v.
the pharmaceutical formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
vials and methods of filing a vial comprising a pharmaceutical formulation described herein comprising a pharmaceutical formulation described herein.
the pharmaceutical formulation is provided inside a vial with a stopper pierceable by a syringe, preferably in aqueous form.
the vial is desirably stored at about 2-8° C. as well as up to 30° C. for 24 hours until it is administered to a subject in need thereof.
the vial may for example be a 15 cc vial (for example for a 600 mg dose) or 20 cc vial (for example for a 900 mg dose).
the pharmaceutical formulation for administration is preferably a liquid formulation (not lyophilized) and has not been subjected to prior lyophilization. While the pharmaceutical formulation may be lyophilized, preferably it is not. In some embodiments of any of the pharmaceutical formulations, the pharmaceutical formulation, the pharmaceutical formulation is a lyophilized pharmaceutical formulation. In some embodiments, the pharmaceutical formulation is a liquid formulation. In some embodiments, the pharmaceutical formulation does not contain a tonicifying amount of a salt such as sodium chloride. In some embodiments of any of the pharmaceutical formulations, the pharmaceutical formulation is diluted.
the pharmaceutical formulation comprising the anti-c-met antibody is stable. In some embodiments, the pharmaceutical formulation comprising the anti-c-met antibody is physically stable. In some embodiments, the pharmaceutical formulation comprising the anti-c-met antibody is chemically stable. In some embodiments, the pharmaceutical formulation comprising the anti-c-met antibody is physically stable and chemically stable. In some embodiments, the pharmaceutical formulation comprises an antagonistic anti-c-met antibody and agonistic activity of the pharmaceutical formulation is substantially undetectable. Methods of detecting agonistic and/or agonistic activity are known in the art, for example, U.S. Pat. No. 6,207,152, which is incorporated by reference in its entirety. In some embodiments, the pharmaceutical formulation is substantially nonimmunogenic.
the pharmaceutical formulation does not significantly result in increased aggregate formation after storage at about 40° C. for about two weeks or about four weeks, at about 25° C. for about one month or about three months; at about 5° C. for about six months, about one year, or about two years, and/or about ⁇ 20° C. for about three months, about six months, or about a year.
the pharmaceutical formulation has reduced or lower levels of aggregate formation after storage at about 40° C. for about two weeks or about four weeks, at about 25° C. for about one month or about three months; at about 5° C. for about six months, about one year, or about two years, and/or about ⁇ 20° C. for about three months, about six months, or about a year (e.g., compared to a similar formulation at pH 5.7).
HMWS High Molecular Weight Species
onartuzumab is about 100 kDa (99,161 Daltons), therefore, a HMWS is greater than about 100 kDa.
the size of a bivalent antibody is approximately 150 kDa and a dimer of onartuzumab is about 200 kDa.
the pharmaceutical formulation comprises less than about any of 1.5%, 1.25%, 1%, 0.75%, 0.5%, 0.25%, 0.20% or 0.15% HMWS (e.g., upon storage). In some embodiments of any of the pharmaceutical formulations, the pharmaceutical formulation does not significantly increase the percentage of HMWS after storage at about 40° C.
the pharmaceutical formulation has reduced or lower levels of HMWS after storage at about 40° C. for about two weeks or about four weeks, at about 25° C. for about one month or about three months; at about 5° C. for about six months, about one year, or about two years, and/or about ⁇ 20° C. for about three months, about six months, or about a year.
the pharmaceutical formulation has reduced or lower levels of HMWS after storage at about 40° C. for about two weeks or about four weeks, at about 25° C. for about one month or about three months; at about 5° C. for about six months, about one year, or about two years, and/or about ⁇ 20° C. for about three months, about six months, or about a year (e.g., compared to a similar formulation at pH 5.7).
the pharmaceutical formulation does not significantly increase the percentage of HMWS after storage at about 40° C. for about any of 15 days, 30 days, 45 days, or 60 days or at about 25° C. for about 30 days or about 60 days. In some embodiments, the pharmaceutical formulation has reduced or lower levels of HMWS after storage at about 40° C. for about any of 15 days, 30 days, 45 days, or 60 days or at about 25° C. for about 30 days or about 60 days (e.g., compared to a similar formulation at pH 5.7).
LMWS Low Molecular Weight Species
onartuzumab is about 100 kDa (99,161 Daltons), therefore, a LMWS is less than about 100 kDa.
the pharmaceutical formulation does not significantly increase degradation and/or percentage of LMWS after storage at about 40° C. for about two weeks or about four weeks, at about 25° C. for about one month or about three months; at about 5° C. for about six months, about one year, or about two years, and/or about ⁇ 20° C. for about three months, about six months, or about a year (e.g., compared to a similar formulation at pH 5.7).
the pharmaceutical formulation does not significantly increase degradation and/or percentage of LMWS after storage at about 40° C. for about any of 15 days, 30 days, 45 days, or 60 days, at about 25° C. for a for about 30 days or about 60 days (e.g., compared to a similar formulation at pH 5.7).
the percentage of intact polysorbate in the pharmaceutical formulation is greater than about any of 75%, 80%, 85%, or 90% after storage at about 40° C. for about two weeks or about four weeks, at about 25° C. for about one month or about three months; at about 5° C. for about six months, about one year, or about two years, and/or about ⁇ 20° C. for about three months, about six months, or about a year.
the percentage of intact polysorbate in the pharmaceutical formulation is greater than about any of 75%, 80%, 85%, or 90% after storage at about 40° C. for about any of one, two, three, four, five, six, seven, or eight weeks.
the percentage of degraded polysorbate in the pharmaceutical formulation is less than about any of 25%, 20%, 15%, or 10% after storage at about 40° C. for about two weeks or about four weeks, at about 25° C. for about one month or about three months; at about 5° C. for about six months, about one year, or about two years, and/or about ⁇ 20° C. for about three months, about six months, or about a year. In some embodiments, the percentage of degraded polysorbate in the pharmaceutical formulation is less than about any of 25%, 20%, 15%, or 10% after storage at about 40° C. for one, two, three, four, five, six, seven, or eight weeks.
the ratio of degraded polysorbate to intact polysorbate in the pharmaceutical formulation is less than about any of 0.25, 0.20, 0.15 or 0.10 after storage at about 40° C. for about two weeks or about four weeks, at about 25° C. for about one month or about three months; at about 5° C. for about six months, about one year, or about two years, and/or about ⁇ 20° C. for about three months, about six months, or about a year.
the ratio of degraded polysorbate to intact polysorbate in the pharmaceutical formulation is less than about any of 0.25, 0.20, 0.15 or 0.10 after storage at about 40° C. for about any of one, two, three, four, five, six, seven, or eight weeks.
the pharmaceutical formulation comprising the anti-c-met antibody is more stable than a similar formulation at pH 5.7 and/or with a polysorbate concentration of 0.02% or less.
the pharmaceutical formulation is desirably one which has been demonstrated to be stable upon storage and/or during administration (e.g., after dilution in an IV bag).
Various stability assays are available to the skilled practitioner for confirming the stability of the formulation.
the formulation may be one which is found to be stable upon storage: at about 25° C. for at least about one month or at least about three months, about 5° C. for at least about six months or at least about one year; and/or about ⁇ 20° C. for at least about six months or at least about one year.
the pharmaceutical formulation is preferably stable following freezing (to, e.g., ⁇ 70° C.) and thawing of the pharmaceutical formulation.
Freezing of the aqueous pharmaceutical formulation without simultaneous drying that occurs during freeze-drying, is specifically contemplated herein, facilitating longer term storage thereof, for instance in a stainless steel tank. Freezing of the pharmaceutical formulation is specifically contemplated herein. Hence, the pharmaceutical formulation can be tested for stability upon freezing and thawing.
the formulation is provided inside a stainless steel tank. The formulation in the stainless steel tank is optionally frozen and not freeze-dried.
the pharmaceutical formulation to be used for in vivo administration should be sterile. This can be achieved according to the procedures known to the skilled person for generating sterile pharmaceutical formulations suitable for administration to human subjects, including filtration through sterile filtration membranes, prior to, or following, preparation of the formulation.
the pharmaceutical formulation comprising the anti-c-met antibody is stable upon dilution with a diluent (e.g., saline).
a diluent e.g., saline
IV bags comprising a diluted pharmaceutical formulation described herein.
the diluent is saline (e.g., 0.9% sodium chloride).
the concentration of the anti-c-met antibody is diluted to about any of 0.5 mg/mL, 1 mg/mL, 1.5 mg/mL, 2 mg/mL, 3 mg/mL, 4 mg/mL or 5 mg/mL.
the concentration of the anti-c-met antibody is diluted to between about any of 0.5-5 mg/mL, 0.5-2.5 mg/mL, or 0.5-1.5 mg/mL. Therefore, for example, provided herein are pharmaceutical formulations comprising a) an anti-c-met antibody, wherein the antibody concentration is about 1 mg/mL, and (b) a polysorbate, wherein the polysorbate concentration is greater than 0.00033% w/v.
the pharmaceutical formulation comprises (a) an anti-c-met antibody, wherein the antibody concentration is about 1 mg/mL; (b) a polysorbate, wherein the polysorbate concentration is greater than 0.00033% w/v; (c) a histidine buffer (e.g., a histidine buffer at a pH between 5.0 and 5.4).
the pharmaceutical formulation is stable (e.g., physically stable) in an IV bag and/or IV administration set.
the pharmaceutical formulation (for example, after dilution) is stable upon agitation for any of about thirty minutes, one hour, 1.5 hours, or two hours at about any of 75, 100, 125, or 150 rpm. In some embodiments of any of the pharmaceutical formulations, the pharmaceutical formulation (for example, after dilution) comprises less than about any of 1.5%, 1.25%, 1%, 0.75%, 0.5%, 0.25%, 0.20% or 0.15% HMWS (for example, upon agitation).
kits for making a pharmaceutical formulation comprising preparing the formulation as described herein.
the methods further comprise evaluating physical stability, chemical stability, or biological activity of the anti-c-met antibody in the formulation.
Stability can be tested by evaluating physical stability, chemical stability, and/or biological activity of the antibody in the formulation around the time of formulation as well as following storage, during administration, and/or upon agitation at the noted temperatures.
Physical and/or stability can be evaluated qualitatively and/or quantitatively in a variety of different ways, including evaluation of aggregate formation (for example using size exclusion chromatography, by measuring turbidity, and/or by visual inspection); by assessing charge heterogeneity using cation exchange chromatography or capillary zone electrophoresis; amino-terminal or carboxy-terminal sequence analysis; mass spectrometric analysis; SDS-PAGE analysis to compare reduced and intact antibody; peptide map (for example tryptic or LYS-C) analysis; evaluating biological activity or antigen binding function of the antibody; etc.
aggregate formation for example using size exclusion chromatography, by measuring turbidity, and/or by visual inspection
charge heterogeneity using cation exchange chromatography or capillary zone electrophoresis
Instability may result in aggregation, deamidation (e.g., Asn deamidation), oxidation (e.g., Met oxidation), isomerization (e.g., Asp isomerization), clipping/hydrolysis/fragmentation (e.g., hinge region fragmentation), succinimide formation, unpaired cysteine(s), N-terminal extension, C-terminal processing, glycosylation differences, etc.
Biological activity or antigen binding function can be evaluated using various techniques available to the skilled practitioner.
One or more other pharmaceutically acceptable carriers, excipients or stabilizers such as those described in Remington's Pharmaceutical Sciences 18th edition, Gennaro, A. Ed. (1990) may be included in the formulation provided that they do not adversely affect the desired characteristics of the formulation.
Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed and include; additional buffering agents; co-solvents; antioxidants including ascorbic acid and methionine; chelating agents such as EDTA; metal complexes (e.g., Zn-protein complexes); biodegradable polymers such as polyesters; preservatives; and/or salt-forming counterions such as sodium.
anti-c-met antibodies for use in the pharmaceutical formulations described herein.
Useful anti-c-met antibodies include antibodies that bind with sufficient affinity and specificity to c-met and can reduce or inhibit one or more c-met activities.
Anti-c-met antibodies in the pharmaceutical formulations can be used to modulate one or more aspects of HGF/c-met-associated effects, including but not limited to c-met activation, downstream molecular signaling (e.g., mitogen activated protein kinase (MAPK) phosphorylation), cell proliferation, cell migration, cell survival, cell morphogenesis and angiogenesis.
downstream molecular signaling e.g., mitogen activated protein kinase (MAPK) phosphorylation
MEPK mitogen activated protein kinase
the anti-c-met antibody is an antagonist anti-c-met antibody.
the anti-c-met antibody interferes with diseases or conditions wherein c-met/HGF activity is involved.
the anti-c-met antibody is an anti-c-met antibody fragment. In some embodiments, the anti-c-met antibody is an antagonist anti-c-met antibody. In some embodiments, the anti-c-met antibody is monovalent. In some embodiments, the anti-c-met antibody fragment may comprise a single antigen binding arm and an Fc region. Anti-c-met antibody fragments are described herein and are known in the art, in the one-armed format.
the anti-c-met antibody fragment is a one-armed antibody (i.e., the heavy chain variable domain and the light chain variable domain form a single antigen binding arm) comprising an Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, wherein the first and second Fc polypeptides are present in a complex.
the first and second Fc polypeptides form a Fc region that increases stability of the anti-c-met antibody compared to a Fab molecule comprising said antigen binding arm.
the anti-c-met antibody comprises (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO:19, a CH1 sequence, and a first Fc polypeptide and (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO:20 and CL1 sequence. In some embodiments, the anti-c-met antibody further comprises (c) a third polypeptide comprising a second Fc polypeptide.
the anti-c-met antibody fragment of the pharmaceutical formulation described herein comprises an antigen binding site of the bivalent antibody and thus retains the ability to bind antigen.
the anti-c-met antibody fragment comprises the Fc region and retains at least one of the biological functions normally associated with the Fc region when present in an bivalent antibody, such as FcRn binding, antibody half life modulation, ADCC function and complement binding.
the anti-c-met antibody fragment does not have ADCC function and/or complement binding activity.
the anti-c-met antibody fragment is a monovalent antibody that has an in vivo half life substantially similar to a bivalent antibody.
an antibody fragment may comprise on antigen binding arm linked to an Fc sequence capable of conferring in vivo stability to the fragment.
an Fc polypeptide comprises part or all of a wild type hinge sequence (generally at its N terminus).
an Fc polypeptide does not comprise a functional or wild type hinge sequence.
the anti-c-met antibody fragment is a one-armed antibody as described in WO2005/063816.
the one-armed antibody comprises Fc mutations constituting “knobs” and “holes” as described in WO2005/063816; Ridgeway, J et al, Prot Eng (1996) 9:617-21; and Zhu Z et al.
the Fc region comprises at least one protuberance (knob) and at least one cavity (hole), wherein presence of the protuberance and cavity enhances formation of a complex between an Fc polypeptide comprising the protuberance and an Fc polypeptide comprising the cavity, for example as described in WO 2005/063816.
the Fc region of the anti-c-met antibodies comprises a first and a second Fc polypeptide, wherein the first and second polypeptide each comprises one or more mutations with respect to wild type human Fc.
a cavity mutation is T366S, L368A and/or Y407V.
a protuberance mutation is T366W.
the first polypeptide comprises the Fc sequence depicted in FIG. 2 and the second polypeptide comprises the Fc sequence depicted in FIG. 3 .
the anti-c-met antibody may comprise at least one characteristic that promotes heterodimerization, while minimizing homodimerization, of the Fc sequences within the antibody fragment.
the anti-c-met antibody is an antagonist anti-c-met antibody.
blocking anti-c-met antibodies or antagonist anti-c-met antibodies completely inhibit the biological activity of the antigen.
the monovalent trait of a one-armed antibody i.e., an antibody comprising a single antigen binding arm results in and/or ensures an antagonistic function upon binding of the anti-c-met antibody to a target molecule.
the one-armed antibody comprising a Fc region is characterized by superior pharmacokinetic attributes (such as an enhanced half life and/or reduced clearance rate in vivo) compared to Fab forms having similar/substantially identical antigen binding characteristics, thus overcoming a major drawback in the use of conventional monovalent Fab antibodies.
Anti-c-met antibodies (which may be provided as one-armed antibodies) useful in the pharmaceutical formulation described herein include those known in the art (see, e.g., Martens, T. et al., Clin. Cancer Res. 12 (20 Pt. 1):6144 (2006); U.S. Pat. No. 6,468,529; WO2006/015371; WO2007/063816, and WO2010/045345, which are incorporated by reference in their entirety).
the anti-c-met antibody for use in the pharmaceutical formulations described herein comprises one or more of the HVR sequences of the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection (ATCC) Accession Number ATCC HB-11894 (hybridoma 1A3.3.13) or HB-11895 (hybridoma 5D5.11.6).
ATCC American Type Culture Collection
the anti-c-met antibody is a one-armed antibody comprising one or more of the HVRs of the light chain variable domain and/or one or more of the HVRs of the heavy chain variable domain of ATCC Accession Number ATCC HB-11894 (hybridoma 1A3.3.13) or HB-11895 (hybridoma 5D5.11.6) and an Fc polypeptide.
the anti-c-met antibody comprises a light chain variable domain comprising one or more of HVR1-LC, HVR2-LC and HVR3-LC sequence depicted in FIG. 2 (SEQ ID NOs:1-3). In some embodiments, the anti-c-met antibody comprises a heavy chain variable domain comprising one or more of HVR1-HC, HVR2-HC and HVR3-HC sequence depicted in FIG. 2 (SEQ ID NOs:4-6). In some embodiments, the anti-c-met antibody comprises a light chain variable domain comprising one or more of HVR1-LC, HVR2-LC and HVR3-LC sequence depicted in FIG.
the heavy chain variable domain comprises one or more of HVR1-HC, HVR2-HC and HVR3-HC sequence depicted in FIG. 2 (SEQ ID NOs:4-6) and one or more of FR1-HC, FR2-HC, FR3-HC and FR4-HC sequence depicted in FIG. 2 (SEQ ID NOs:11-14).
the light chain variable domain comprises one or more of HVR1-LC, HVR2-LC and HVR3-LC sequence depicted in FIG.
the anti-c-met antibody is a one-armed antibody comprising one or more of the HVRs of the light chain variable domain (SEQ ID NOs:1-3) and/or one or more of the HVRs of the heavy chain variable domain (SEQ ID NOs:4-6) and an Fc polypeptide.
the anti-c-met antibody comprises: (a) at least one, two, three, four, or five HVR sequences selected from the group consisting of: (i) HVR-L1 comprising sequence A1-A17, wherein A1-A17 is KSSQSLLYTSSQKNYLA (SEQ ID NO:23) (ii) HVR-L2 comprising sequence B1-B7, wherein B1-B7 is WASTRES (SEQ ID NO:24); (iii) HVR-L3 comprising sequence C1-C9, wherein C1-C9 is QQYYAYPWT (SEQ ID NO:25); (iv) HVR-H1 comprising sequence D1-D10, wherein D1-D10 is GYTFTSYWLH (SEQ ID NO:26); (v) HVR-H2 comprising sequence E1-E18, wherein E1-E18 is GMIDPSNSDTRFNPNFKD (SEQ ID NO:23) (ii) HVR-L2 compris
HVR-L1 of the anti-c-met antibody comprises the sequence of SEQ ID NO:23.
HVR-L2 comprises the sequence of SEQ ID NO:24.
HVR-L3 comprises the sequence of SEQ ID NO:25.
HVR-H1 comprises the sequence of SEQ ID NO:26.
HVR-H2 comprises the sequence of SEQ ID NO:27.
HVR-H3 the sequence of SEQ ID NO:28.
HVR-H3 comprises TYGSYVSPLDY (SEQ ID NO: 29).
HVR-H3 comprises SYGSYVSPLDY (SEQ ID NO:30).
the anti-c-met antibody comprising these sequences is humanized or human.
the anti-c-met antibody is a one-armed antibody comprising one or more of the HVRs of the light chain variable domain (SEQ ID NOs:23-25) and/or one or more of the HVRs of the heavy chain variable domain (SEQ ID NOs:26-30) and an Fc polypeptide.
anti-c-met antibodies for use in the pharmaceutical formulation comprising one, two, three, four, five or six HVRs, wherein each HVR comprises, consists or consists essentially of a sequence selected from the group consisting of SEQ ID NOs:23, 24, 25, 26, 27, 28, and 29, and wherein SEQ ID NO:23 corresponds to an HVR-L1, SEQ ID NO:24 corresponds to an HVR-L2, SEQ ID NO:25 corresponds to an HVR-L3, SEQ ID NO:26 corresponds to an HVR-H1, SEQ ID NO:27 corresponds to an HVR-H2, and SEQ ID NOs:26, 27, or 28 corresponds to an HVR-H3.
the anti-c-met antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NOs:23, 24, 25, 26, 27 and 29. In some embodiments, the anti-c-met antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NOs:23, 24, 25, 26, 27 and 30.
Variant HVRs can have modifications of one or more residues within the HVR.
a HVR-L2 variant comprises 1-5 (1, 2, 3, 4 or 5) substitutions in any combination of the following positions: B1 (M or L), B2 (P, T, G or S), B3 (N, G, R or T), B4 (I, N or F), B5 (P, I, L or G), B6 (A, D, T or V) and B7 (R, I, M or G).
a HVR-H1 variant comprises 1-5 (1, 2, 3, 4 or 5) substitutions in any combination of the following positions: D3 (N, P, L, S, A, I), D5 (I, S or Y), D6 (G, D, T, K, R), D7 (F, H, R, S, T or V) and D9 (M or V).
a HVR-H2 variant comprises 1-4 (1, 2, 3 or 4) substitutions in any combination of the following positions: E7 (Y), E9 (I), E 10 (I), E14 (T or Q), E15 (D, K, S, T or V), E16 (L), E17 (E, H, N or D) and E18 (Y, E or H).
a HVR-H3 variant comprises 1-5 (1, 2, 3, 4 or 5) substitutions in any combination of the following positions: F1 (T, S), F3 (R, S, H, T, A, K), F4 (G), F6 (R, F, M, T, E, K, A, L, W), F7 (L, I, T, R, K, V), F8 (S, A), F10 (Y, N) and F11 (Q, S, H, F).
a HVR-L1 comprises the sequence of SEQ ID NO:23.
F1 in a variant HVR-H3 is T.
F1 in a variant HVR-H3 is S.
F3 in a variant HVR-H3 is R.
F3 in a variant HVR-H3 is S.
F7 in a variant HVR-H3 is T.
the anti-c-met antibody comprises a variant HVR-H3 wherein F1 is T or S, F3 is R or S, and F7 is T.
the anti-c-met antibody of the pharmaceutical formulation comprises a variant HVR-H3 wherein F1 is T, F3 is R and F7 is T. In some embodiments, the anti-c-met antibody comprises a variant HVR-H3 wherein F1 is S. In some embodiments, the anti-c-met antibody comprises a variant HVR-H3 wherein F1 is T, and F3 is R. In some embodiments, the anti-c-met antibody comprises a variant HVR-H3 wherein F1 is S, F3 is R and F7 is T. In some embodiments, the anti-c-met antibody comprises a variant HVR-H3 wherein F1 is T, F3 is S, F7 is T, and F8 is S.
the anti-c-met antibody comprises a variant HVR-H3 wherein F1 is T, F3 is S, F7 is T, and F8 is A.
said variant HVR-H3 antibody further comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1 and HVR-H2 wherein each comprises, in order, the sequence depicted in SEQ ID NOs:1, 2, 3, 4 and 5.
these antibodies further comprise a human subgroup III heavy chain framework consensus sequence.
the framework consensus sequence comprises substitution at position 71, 73 and/or 78.
position 71 is A
73 is T and/or 78 is A.
these antibodies further comprise a human ⁇ I light chain framework consensus sequence.
the anti-c-met antibody of the pharmaceutical formulation comprises a variant HVR-L2 wherein B6 is V.
said variant HVR-L2 anti-c-met antibody further comprises HVR-L1, HVR-L3, HVR-H1, HVR-H2 and HVR-H3, wherein each comprises, in order, the sequence depicted in SEQ ID NOs:23, 25, 26, 27 and 28.
said variant HVR-L2 anti-c-met antibody further comprises HVR-L1, HVR-L3, HVR-H1, HVR-H2 and HVR-H3, wherein each comprises, in order, the sequence depicted in SEQ ID NOs:23, 25, 26, 27 and 29.
said variant HVR-L2 anti-c-met antibody further comprises HVR-L1, HVR-L3, HVR-H1, HVR-H2 and HVR-H3, wherein each comprises, in order, the sequence depicted in SEQ ID NOs:23, 25, 26, 27 and 30.
these anti-c-met antibodies further comprise a human subgroup III heavy chain framework consensus sequence.
the framework consensus sequence comprises substitution at position 71, 73 and/or 78.
position 71 is A
73 is T and/or 78 is A.
these anti-c-met antibodies these antibodies further comprise a human ⁇ I light chain framework consensus sequence.
the anti-c-met antibody of the pharmaceutical formulation comprises a variant HVR-H2 wherein E14 is T, E15 is K and E17 is E.
the anti-c-met antibody comprises a variant HVR-H2 wherein E17 is E.
said variant HVR-H3 anti-c-met antibody further comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, and HVR-H3 wherein each comprises, in order, the sequence depicted in SEQ ID NOs:23, 24, 25, 26, and 28.
said variant HVR-H2 anti-c-met antibody further comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, and HVR-H3, wherein each comprises, in order, the sequence depicted in SEQ ID NOs:23, 24, 25, 26, and 29.
said variant HVR-H2 anti-c-met antibody further comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, and HVR-H3, wherein each comprises, in order, the sequence depicted in SEQ ID NOs:23, 24, 25, 26 and 30.
these anti-c-met antibodies further comprise a human subgroup III heavy chain framework consensus sequence.
the framework consensus sequence comprises substitution at position 71, 73 and/or 78. In some embodiments of these anti-c-met antibodies, position 71 is A, 73 is T and/or 78 is A. In some embodiments of these antibodies, these anti-c-met antibodies further comprise a human ⁇ I light chain framework consensus sequence.
the anti-c-met antibody of the pharmaceutical formulation comprises (a) a heavy chain variable domain comprising the sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTR FNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVS S (SEQ ID NO:19) and/or (b) a light chain variable domain comprising the sequence: DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTR ESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKR (SEQ ID NO:20).
the anti-c-met antibody is a one-armed antibody comprising (a) the light chain variable domain (SEQ ID NO:20) and/or (b) the heavy chain variable domain (SEQ ID NO:19) and (c) a Fc polypeptide.
the anti-c-met antibody of the pharmaceutical formulation comprises (a) HVR-H1, HVR-H2, and HVR-H3 of a heavy chain variable domain comprising the sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTR FNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVS S (SEQ ID NO:19) and/or (b) HVR-L1, HVR-L2, and HVR-L3 of a light chain variable domain comprising the sequence: DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTR ESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKR (SEQ ID NO:20).
the anti-c-met antibody is a one-armed antibody comprising (a) the light chain variable domain (SEQ ID NO:20) and/or (b) the heavy chain variable domain (SEQ ID NO:19) and (c) a Fc polypeptide.
the anti-c-met antibody of the pharmaceutical formulation is an anti-c-met antibody fragment, wherein the antibody fragment comprises (a) a first polypeptide comprising a heavy chain variable domain comprising SEQ ID NO:19, CH1 sequence (e.g., SEQ ID NO:16), and a first Fc polypeptide; and (b) a second polypeptide comprising a light chain variable domain comprising SEQ ID NO:20, and CL1 sequence (e.g., SEQ ID NO:15).
the antibody fragment comprises (a) a first polypeptide comprising a heavy chain variable domain comprising SEQ ID NO:19, CH1 sequence (e.g., SEQ ID NO:16), and a first Fc polypeptide; and (b) a second polypeptide comprising a light chain variable domain comprising SEQ ID NO:20, and CL1 sequence (e.g., SEQ ID NO:15).
the anti-c-met antibody of the pharmaceutical formulation is an anti-c-met antibody fragment, wherein the antibody fragment comprises (a) a first polypeptide comprising a heavy chain variable domain comprising SEQ ID NO:19, CH1 sequence (e.g., SEQ ID NO:16), and a first Fc polypeptide; (b) a second polypeptide comprising a light chain variable domain comprising SEQ ID NO:20, and CL1 sequence (e.g., SEQ ID NO:15); and (c) a third polypeptide comprising a second Fc polypeptide, wherein the heavy chain variable domain and the light chain variable domain are present as a complex and form a single antigen binding arm and wherein the first and second Fc polypeptides are present in a complex.
the antibody fragment comprises (a) a first polypeptide comprising a heavy chain variable domain comprising SEQ ID NO:19, CH1 sequence (e.g., SEQ ID NO:16), and a first Fc polypeptide; (b) a
the first and second Fc polypeptides form a Fc region that increases stability of said antibody fragment compared to a Fab molecule comprising said antigen binding arm.
the Fc region is that of a human IgG (e.g., IgG1, 2, 3 or 4).
the first Fc polypeptide comprises the Fc sequence depicted in FIG. 2 (SEQ ID NO:17) and the second Fc polypeptide comprises the Fc sequence depicted in FIG. 3 (SEQ ID NO:18).
the first Fc polypeptide comprises the Fc sequence depicted in FIG. 3 (SEQ ID NO:18) and the second Fc polypeptide comprises the Fc sequence depicted in FIG. 2 (SEQ ID NO:17).
the anti-c-met antibody is an anti-c-met antibody or antibody fragment thereof, wherein the antibody comprises (a) a first polypeptide comprising a heavy chain variable domain comprising SEQ ID NO:19, CH1 sequence, and a first Fc polypeptide; (b) a second polypeptide comprising a light chain variable domain comprising SEQ ID NO:20, and CL1 sequence; and (c) a third polypeptide comprising a second Fc polypeptide, wherein the heavy chain variable domain and the light chain variable domain are present as a complex and form a single antigen binding arm, wherein the first and second Fc polypeptides are present in a complex and form a Fc region that increases stability of said antibody fragment compared to a Fab molecule comprising said antigen binding arm.
the anti-c-met antibody comprises (a) a first polypeptide comprising a heavy chain variable domain, said polypeptide comprising the sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFT SYWLHWVRQAPGKGLEWVGMIDPSNS FNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQV
polynucleotides encoding any of the anti-c-met antibodies described herein are expressed such that the anti-c-met antibody is produced. In some embodiments, polynucleotides encoding any of the anti-c-met antibody are expressed in vitro or in vivo (for example, in CHO cells or E. coli cells).
the anti-c-met antibody for use in the pharmaceutical formulation described herein is onartuzumab (interchangeably termed MetMAb), a one-armed antibody comprising a Fc region.
MetMAb a one-armed antibody comprising a Fc region.
FIGS. 2 and 3 A sequence of MetMAb is shown in FIGS. 2 and 3 .
MetMAb also termed OA5D5v2 and onartuzumab
OA5D5v2 also termed OA5D5v2 and onartuzumab
Biosimilar version of MetMAb are also contemplated and encompassed herein for use in the formulation.
the anti-c-met antibody of the pharmaceutical formulation specifically binds at least a portion of c-met Sema domain or variant thereof.
the anti-c-met antibody is an antagonist.
the anti-c-met antagonist antibody specifically binds at least one of the sequences selected from the group consisting of LDAQT (SEQ ID NO:31) (e.g., residues 269-273 of c-met), LTEKRKKRS (SEQ ID NO:32) (e.g., residues 300-308 of c-met), KPDSAEPM (SEQ ID NO: 33) (e.g., residues 350-357 of c-met) and NVRCLQHF (SEQ ID NO:34) (e.g., residues 381-388 of c-met).
LDAQT SEQ ID NO:31
LTEKRKKRS SEQ ID NO:32
KPDSAEPM SEQ ID NO: 33
NVRCLQHF SEQ ID NO:34
the anti-c-met antagonist antibody specifically binds a conformational epitope formed by part or all of at least one of the sequences selected from the group consisting of LDAQT (SEQ ID NO:31) (e.g., residues 269-273 of c-met), LTEKRKKRS (SEQ ID NO:32) (e.g., residues 300-308 of c-met), KPDSAEPM (SEQ ID NO: 33) (e.g., residues 350-357 of c-met) and NVRCLQHF (SEQ ID NO:34) (e.g., residues 381-388 of c-met).
LDAQT SEQ ID NO:31
LTEKRKKRS SEQ ID NO:32
KPDSAEPM SEQ ID NO: 33
NVRCLQHF SEQ ID NO:34
an antagonist antibody specifically binds an amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 95%, 98% sequence identity or similarity with the sequence LDAQT (SEQ ID NO:31), LTEKRKKRS (SEQ ID NO:32), KPDSAEPM (SEQ ID NO:33) and/or NVRCLQHF (SEQ ID NO:34).
the anti-c-met antibody is an antagonist anti-c-met antibody.
the anti-c-met antibody is a one-armed antibody.
the anti-c-met antibody may interfere with HGF/c-met activation, including but not limited to interfering with HGF binding to the extracellular portion of c-met and receptor multimerization.
the anti-c-met antibody are useful in treating or diagnosing pathological conditions associated with abnormal or unwanted signaling of the HGF/c-met pathway.
the anti-c-met antibody may modulate the HGF/c-met pathway, including modulation of c-met ligand binding, c-met dimerization, activation, and other biological/physiological activities associated with HGF/c-met signaling.
the anti-c-met antibody may disrupt HGF/c-met signaling pathway. In some embodiments of any of the anti-c-met antibodies described herein, binding of the anti-c-met antibody to c-met inhibits c-met activation by HGF. In some embodiments of any of the anti-c-met antibodies described herein, binding of the anti-c-met antibody to c-met in a cell inhibits proliferation, survival, scattering, morphogenesis and/or motility of the cell.
an anti-c-met antibody that does not interfere with binding of a ligand (such as HGF) to c-met. Accordingly, in some embodiments, the anti-c-met antibody does not bind an HGF binding site on c-met. In some embodiment, the anti-c-met antibody does not substantially inhibit HGF binding to c-met. In some embodiments, the anti-c-met antibody does not substantially compete with HGF for binding to c-met. In one example, the anti-c-met antibody can be used in conjunction with one or more other antagonists, wherein the antagonists are targeted at different processes and/or functions within the HGF/c-met axis.
the anti-c-met antibody binds to an epitope on c-met distinct from an epitope bound by another c-met antagonist (such as the Fab fragment of the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-11894 (hybridoma 1A3.3.13)).
another c-met antagonist such as the Fab fragment of the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-11894 (hybridoma 1A3.3.13).
the anti-c-met antibody is distinct from (i.e., it is not) a Fab fragment of the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-11894 (hybridoma 1A3.3.13).
the anti-c-met antibody binds to c-met of a first animal species, and does not specifically bind to c-met of a second animal species.
the first animal species is human and/or primate (e.g., cynomolgus monkey), and the second animal species is murine (e.g., mouse) and/or canine.
the first animal species is human.
the first animal species is primate, for example cynomolgus monkey.
the second animal species is murine, for example mouse.
the second animal species is canine.
the anti-c-met antibody elicits little to no immunogenic response in said subject. In some embodiments, the anti-c-met antibody elicits an immunogenic response at or less than a clinically-acceptable level.
an altered antibody that possesses some but not all effector functions in some embodiments, the anti-c-met antibody does not possess complement depletion and/or ADCC activity. In some embodiments, the Fc activities of the produced immunoglobulin are measured to ensure that only the desired properties are maintained (e.g., half-life but not complement depletion and/or ADCC activity). In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities.
Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks Fc ⁇ R binding (hence likely lacking ADCC activity), but retains FcRn binding ability.
FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991).
An example of an in vitro assay to assess ADCC activity of a molecule of interest is described in U.S. Pat. No. 5,500,362 or 5,821,337.
PBMC peripheral blood mononuclear cells
NK Natural Killer
ADCC activity of the molecule of interest may be assessed in vivo, e.g., in a animal model such as that disclosed in Clynes et al. PNAS ( USA ) 95:652-656 (1998).
C1q binding assays may also be carried out to confirm that the antibody is unable to bind C1q and hence lacks CDC activity.
a CDC assay e.g. as described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996), may be performed.
the anti-c-met antibody is glycosylated. In some embodiments, the anti-c-met antibody is substantially aglycosylated.
the anti-c-met antibodies of the formulations described herein can be characterized for their physical/chemical properties and biological functions by various assays known in the art.
the purified anti-c-met antibodies can be further characterized by a series of assays including, but not limited to, N-terminal sequencing, amino acid analysis, non-denaturing size exclusion high pressure liquid chromatography (HPLC), mass spectrometry, ion exchange chromatography and papain digestion.
the anti-c-met antibody may be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue, or silver stain.
the anti-c-met antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in Sections 1-8 below:
the anti-c-met antibody provided herein has a dissociation constant (Kd) of ⁇ 1 ⁇ M, ⁇ 100 nM, ⁇ 10 nM, ⁇ 1 nM, ⁇ 0.1 nM, ⁇ 0.01 nM, or ⁇ 0.001 nM (e.g. 10 ⁇ 8 M or less, e.g. from 10 ⁇ 8 M to 10 ⁇ 13 M, e.g., from 10 ⁇ 9 M to 10 ⁇ 13 M).
Kd dissociation constant
Binding affinity of a ligand to its receptor can be determined using any of a variety of assays, and expressed in terms of a variety of quantitative values.
Antigen binding assays are known in the art and can be used herein include without limitation any direct or competitive binding assays using techniques such as western blots, radioimmunoassays, enzyme-linked immunoabsorbent assay (ELISA), “sandwich” immunoassays, surface plasmon resonance based assay (such as the BIAcore assay as described in PCT Application Publication No. WO2005/012359), immunoprecipitation assays, fluorescent immunoassays, and protein A immunoassays.
the binding affinity is expressed as Kd values and reflects intrinsic binding affinity (e.g., with minimized avidity effects).
the anti-c-met antibody selected will normally have a sufficiently strong binding affinity for c-met, for example, the antibody may bind human c-met with a Kd value of between 100 nM ⁇ 1 pM.
the anti-c-met antibody of the pharmaceutical formulation described herein is an antibody fragment.
Antibody fragments include, but are not limited to, Fab, Fab′, Fab′-SH, F(ab′) 2 , Fv, one-armed antibodies, and scFv fragments, and other fragments described below.
Fab fragment antigen
Fab′ fragment antigen binding protein
Fab′-SH fragment antigen binding protein
Fv Fv
one-armed antibodies Fv
scFv fragments fragments described below.
scFv fragments see, e.g., Pluckthün, in The Pharmacology of Monoclonal Antibodies , vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp.
Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody.
a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, Mass.; see, e.g., U.S. Pat. No. 6,248,516 B1).
Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. E. coli or phage), as described herein.
recombinant host cells e.g. E. coli or phage
the anti-c-met antibody of the pharmaceutical formulation described herein is a chimeric antibody.
Certain chimeric antibodies are described, e.g., in U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).
a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region.
a chimeric antibody is a “class switched” antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
a chimeric antibody is a humanized antibody.
a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody.
a humanized antibody comprises one or more variable domains in which HVRs, e.g., CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences.
HVRs e.g., CDRs, (or portions thereof) are derived from a non-human antibody
FRs or portions thereof
a humanized antibody optionally will also comprise at least a portion of a human constant region.
some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the CDR residues are derived), e.g., to restore or improve antibody specificity or affinity.
a non-human antibody e.g., the antibody from which the CDR residues are derived
Human framework regions that may be used for humanization include but are not limited to: framework regions selected using the “best-fit” method (see, e.g., Sims et al. J. Immunol. 151:2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter et al. Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al. J. Immunol., 151:2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci.
the anti-c-met antibody of the pharmaceutical formulation described herein is a human antibody.
Human antibodies can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).
Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge.
Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or which are present extrachromosomally or integrated randomly into the animal's chromosomes.
the endogenous immunoglobulin loci have generally been inactivated.
Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g., Kozbor J. Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications , pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147: 86 (1991).) Human antibodies generated via human B-cell hybridoma technology are also described in Li et al., Proc. Natl. Acad. Sci. USA, 103:3557-3562 (2006).
Additional methods include those described, for example, in U.S. Pat. No. 7,189,826 (describing production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4):265-268 (2006) (describing human-human hybridomas).
Human hybridoma technology Trioma technology
Vollmers and Brandlein, Histology and Histopathology, 20(3):927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27(3):185-91 (2005).
Human antibodies may also be generated by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described below.
the anti-c-met antibody of the pharmaceutical formulation described herein may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed, e.g., in Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, N.J., 2001) and further described, e.g., in the McCafferty et al., Nature 348:552-554; Clackson et al., Nature 352: 624-628 (1991); Marks et al., J.
repertoires of V H and V L genes are separately cloned by polymerase chain reaction (PCR) and recombined randomly in phage libraries, which can then be screened for antigen-binding phage as described in Winter et al., Ann. Rev. Immunol., 12: 433-455 (1994).
Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments.
naive repertoire can be cloned (e.g., from human) to provide a single source of antibodies to a wide range of non-self and also self antigens without any immunization as described by Griffiths et al., EMBO J, 12: 725-734 (1993).
naive libraries can also be made synthetically by cloning unrearranged V-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement in vitro, as described by Hoogenboom and Winter, J. Mol. Biol., 227: 381-388 (1992).
Patent publications describing human antibody phage libraries include, for example: U.S. Pat. No. 5,750,373, and US Patent Publication Nos. 2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598, 2007/0237764, 2007/0292936, and 2009/0002360.
Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.
the anti-c-met antibody of the pharmaceutical formulation described herein is a multispecific antibody, e.g. a bispecific antibody.
Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. In some embodiments, one of the binding specificities is for an antigen and the other is for any other antigen.
bispecific antibodies may bind to two different epitopes of an antigen. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express an antigen. Bispecific antibodies can be prepared as full length antibodies or antibody fragments.
Multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein and Cuello, Nature 305: 537 (1983)), WO 93/08829, and Traunecker et al., EMBO J. 10: 3655 (1991)), and “knob-in-hole” engineering (see, e.g., U.S. Pat. No. 5,731,168). Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004A1); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No.
the antibody or fragment herein also includes a “Dual Acting FAb” or “DAF” comprising an antigen binding site that binds to c-met as well as another, different antigen (see, US 2008/0069820, for example).
DAF Double Acting FAb
amino acid sequence variants of the anti-c-met antibody for use in the pharmaceutical formulation described herein are contemplated.
Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding.
anti-c-met antibody variants having one or more amino acid substitutions for use in the pharmaceutical formulation described herein are provided.
Sites of interest for substitutional mutagenesis include the HVRs and FRs.
Conservative substitutions are shown in Table 1 under the heading of “conservative substitutions.” More substantial changes are provided in Table 1 under the heading of “exemplary substitutions,” and as further described below in reference to amino acid side chain classes.
Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.
Amino acids may be grouped according to common side-chain properties:
H is, Lys, Arg
Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g. a humanized or human antibody).
a parent antibody e.g. a humanized or human antibody
the resulting variant(s) selected for further study will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antibody and/or will have substantially retained certain biological properties of the parent antibody.
An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, e.g., using phage display-based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and the variant antibodies displayed on phage and screened for a particular biological activity (e.g. binding affinity).
Alterations may be made in HVRs, e.g., to improve antibody affinity. Such alterations may be made in HVR “hotspots,” i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, Methods Mol. Biol. 207:179-196 (2008)), and/or SDRs (a-CDRs), with the resulting variant V H or V L being tested for binding affinity.
HVR “hotspots” i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, Methods Mol. Biol. 207:179-196 (2008)), and/or SDRs (a-CDRs), with the resulting variant V H or V L being tested for binding affinity.
Affinity maturation by constructing and reselecting from secondary libraries has been described, e.g., in Hoogenboom
affinity maturation diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis).
a secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity.
Another method to introduce diversity involves HVR-directed approaches, in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding may be specifically identified, e.g., using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted.
substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen.
conservative alterations e.g., conservative substitutions as provided herein
Such alterations may be outside of HVR “hotspots” or SDRs.
each HVR either is unaltered, or contains no more than one, two or three amino acid substitutions.
a useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called “alanine scanning mutagenesis” as described by Cunningham and Wells (1989) Science, 244:1081-1085.
a residue or group of target residues e.g., charged residues such as arg, asp, his, lys, and glu
a neutral or negatively charged amino acid e.g., alanine or polyalanine
Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions.
a crystal structure of an antigen-antibody complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution.
Variants may be screened to determine whether they contain the desired properties.
Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
terminal insertions include an antibody with an N-terminal methionyl residue.
Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases the serum half-life of the antibody.
the anti-c-met antibody of the pharmaceutical formulation described herein is altered to increase or decrease the extent to which the antibody is glycosylated.
Addition or deletion of glycosylation sites to an antibody may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites is created or removed.
the carbohydrate attached thereto may be altered.
Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al. TIBTECH 15:26-32 (1997).
the oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the “stem” of the biantennary oligosaccharide structure.
modifications of the oligosaccharide in an antibody may be made in order to create antibody variants with certain improved properties.
antibody variants having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region.
the amount of fucose in such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65% or from 20% to 40%.
the amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297, relative to the sum of all glycostructures attached to Asn 297 (e.g. complex, hybrid and high mannose structures) as measured by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for example.
Asn297 refers to the asparagine residue located at about position 297 in the Fc region (Eu numbering of Fc region residues); however, Asn297 may also be located about ⁇ 3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function. See, e.g., US Patent Publication Nos. US 2003/0157108 (Presta, L.); US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd).
Examples of publications related to “defucosylated” or “fucose-deficient” antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; WO2005/053742; WO2002/031140; Okazaki et al. J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al. Biotech. Bioeng.
Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells deficient in protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533-545 (1986); US Pat Appl No US 2003/0157108 A1, Presta, L; and WO 2004/056312 A1, Adams et al., especially at Example 11), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004); Kanda, Y. et al., Biotechnol. Bioeng., 94(4):680-688 (2006); and WO2003/085107).
Antibodies variants are further provided with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and/or improved ADCC function. Examples of such antibody variants are described, e.g., in WO 2003/011878 (Jean-Mairet et al.); U.S. Pat. No. 6,602,684 (Umana et al.); and US 2005/0123546 (Umana et al.). Antibody variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided.
Such antibody variants may have improved CDC function.
Such antibody variants are described, e.g., in WO 1997/30087 (Patel et al.); WO 1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.).
one or more amino acid modifications may be introduced into the Fc region of the anti-c-met antibody of the pharmaceutical formulation described herein, thereby generating an Fc region variant.
the Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g. a substitution) at one or more amino acid positions.
contemplated are antibody variants that possesses some but not all effector functions, which make it a desirable candidate for applications in which the half life of the antibody in vivo is important yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious.
In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities.
Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks Fc ⁇ R binding (hence likely lacking ADCC activity), but retains FcRn binding ability.
NK cells express Fc ⁇ RIII only, whereas monocytes express Fc ⁇ RI, Fc ⁇ RII and Fc ⁇ RIII.
FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991).
Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest is described in U.S. Pat. Nos. 5,500,362 (see, e.g. Hellstrom, I. et al. Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I et al., Proc.
non-radioactive assays methods may be employed (see, for example, ACTITM non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, Calif.; and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, Wis.).
Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells.
ADCC activity of the molecule of interest may be assessed in vivo, e.g., in a animal model such as that disclosed in Clynes et al. Proc. Nat'l Acad. Sci. USA 95:652-656 (1998).
C1q binding assays may also be carried out to confirm that the antibody is unable to bind C1q and hence lacks CDC activity. See, e.g., C1q and C3c binding ELISA in WO 2006/029879 and WO 2005/100402.
a CDC assay may be performed (see, for example, Gazzano-Santoro et al., J. Immunol.
FcRn binding and in vivo clearance/half life determinations can also be performed using methods known in the art (see, e.g., Petkova, S. B. et al., Int'l. Immunol. 18(12):1759-1769 (2006)).
Antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Pat. No. 6,737,056).
Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called “DANA” Fc mutant with substitution of residues 265 and 297 to alanine (U.S. Pat. No. 7,332,581).
an antibody variant comprises an Fc region with one or more amino acid substitutions which improve ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering of residues).
alterations are made in the Fc region that result in altered (i.e., either improved or diminished) C1q binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551, WO 99/51642, and Idusogie et al. J. Immunol. 164: 4178-4184 (2000).
CDC Complement Dependent Cytotoxicity
Antibodies with increased half lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus are described in US2005/0014934A1 (Hinton et al.). Those antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn.
Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (U.S. Pat. No. 7,371,826).
cysteine engineered antibodies e.g., “thioMAbs,” in which one or more residues of the anti-c-met antibody of the pharmaceutical formulation described herein are substituted with cysteine residues.
the substituted residues occur at accessible sites of the antibody.
reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate, as described further herein.
any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and 5400 (EU numbering) of the heavy chain Fc region.
Cysteine engineered antibodies may be generated as described, e.g., in U.S. Pat. No. 7,521,541.
the anti-c-met antibody of the pharmaceutical formulation described herein may be further modified to contain additional nonproteinaceous moieties that are known in the art and readily available.
the moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers.
Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, prolypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof.
PEG polyethylene glycol
copolymers of ethylene glycol/propylene glycol carboxymethylcellulose
dextran polyvinyl alcohol
Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water.
the polymer may be of any molecular weight, and may be branched or unbranched.
the number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.
conjugates of the anti-c-met antibody and nonproteinaceous moiety that may be selectively heated by exposure to radiation are provided.
the nonproteinaceous moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)).
the radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the nonproteinaceous moiety to a temperature at which cells proximal to the antibody-nonproteinaceous moiety are killed.
Immunoconjugates comprising the anti-c-met antibody conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), or radioactive isotopes are contemplated for use in the pharmaceutical formulation described herein.
cytotoxic agents such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), or radioactive isotopes are contemplated for use in the pharmaceutical formulation described herein.
an immunoconjugate is an antibody-drug conjugate (ADC) in which an antibody is conjugated to one or more drugs, including but not limited to a maytansinoid (see U.S. Pat. Nos. 5,208,020, 5,416,064 and European Patent EP 0 425 235 B1); an auristatin such as monomethylauristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Pat. Nos. 5,635,483 and 5,780,588, and 7,498,298); a dolastatin; a calicheamicin or derivative thereof (see U.S. Pat. Nos.
ADC antibody-drug conjugate
drugs including but not limited to a maytansinoid (see U.S. Pat. Nos. 5,208,020, 5,416,064 and European Patent EP 0 425 235 B1); an auristatin such as monomethylauristatin drug moieties DE and DF (MMAE and
an immunoconjugate comprises the anti-c-met antibody as described herein conjugated to an enzymatically active toxin or fragment thereof, including but not limited to diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa ), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.
an enzymatically active toxin or fragment thereof including but not limited to diphtheria A chain, nonbinding active fragments of diphtheria toxin, exo
an immunoconjugate comprises the anti-c-met antibody as described herein conjugated to a radioactive atom to form a radioconjugate.
a radioactive atom to form a radioconjugate.
radioactive isotopes are available for the production of radioconjugates. Examples include At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 and radioactive isotopes of Lu.
the radioconjugate When used for detection, it may comprise a radioactive atom for scintigraphic studies, for example Tc99m or I123, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), such as iodine-123 again, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.
NMR nuclear magnetic resonance
Conjugates of the anti-c-met antibody and cytotoxic agent may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis(p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine
a ricin immunotoxin can be prepared as described in Vitetta et al., Science 238:1098 (1987).
Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.
the linker may be a “cleavable linker” facilitating release of a cytotoxic drug in the cell.
an acid-labile linker, peptidase-sensitive linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari et al., Cancer Res. 52:127-131 (1992); U.S. Pat. No. 5,208,020) may be used.
the immunuoconjugates or ADCs herein expressly contemplate, but are not limited to such conjugates prepared with cross-linker reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfone)benzoate) which are commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, Ill., U.S.A).
cross-linker reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC
the anti-c-met antibody for use in any of the pharmaceutical formulations described herein may be produced recombinant methods and compositions, e.g., as described in U.S. Pat. No. 4,816,567.
isolated nucleic acid encoding an antibody is provided. Such nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody).
one or more vectors e.g., expression vectors
a host cell comprising such nucleic acid is provided.
a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody.
Production of a one-armed antibody is described, e.g., in WO2005/063816.
the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell).
a method of making an antibody comprises culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).
nucleic acid encoding an antibody is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell.
nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).
Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein.
antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed.
For expression of antibody fragments and polypeptides in bacteria see, e.g., U.S. Pat. Nos. 5,648,237, 5,789,199, and 5,840,523, WO/2017063816. (See also Charlton, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J., 2003), pp. 245-254, describing expression of antibody fragments in E. coli .)
the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.
eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006).
Suitable host cells for the expression of glycosylated antibody are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.
Plant cell cultures can also be utilized as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIESTM technology for producing antibodies in transgenic plants).
Vertebrate cells may also be used as hosts.
mammalian cell lines that are adapted to grow in suspension may be useful.
Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, Biol. Reprod.
monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TR1 cells, as described, e.g., in Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC 5 cells; and FS4 cells.
Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells (Urlaub et al., Proc. Natl. Acad. Sci.
the pharmaceutical formulations provided herein comprising an anti-c-met antibody are useful for modulating disease states associated with dysregulation of the HGF/c-met signaling axis.
the HGF/c-met signaling pathway is involved in multiple biological and physiological functions, including, e.g., cell proliferation and angiogenesis.
a method of inhibiting c-met activated cell proliferation comprising contacting a cell or tissue with a pharmaceutical formulation described herein (e.g., upon dilution (e.g., a diluted pharmaceutical formulation described herein)) comprising an effective amount of an anti-c-met antibody, whereby cell proliferation associated with c-met activation is inhibited.
the cell proliferative disorder is associated with increased expression or activity of c-met or hepatocyte growth, or both.
the cancer is c-met positive (expresses high levels of c-met, for example, by immunohistochemistry).
the cell proliferation is cancer.
the cancer is non-small cell lung cancer (NSCLC), glioblastoma, pancreatic cancer, sarcoma, renal cell carcinoma, hepatocellular carcinoma, gastric cancer, colorectal cancer, or breast cancer.
NSCLC non-small cell lung cancer
the cancer is stage IIIb and/or stage IV.
the cancer is locally advanced or metastatic cancer.
the therapy is second line or third line therapy (e.g., second line or third line NSCLC therapy).
the cancer is EGFR mutant.
the cancer is EGFR wild-type.
the cancer is c-met positive (expresses high levels of c-met, for example, by immunohistochemistry (IHC)).
the pharmaceutical formulation comprises (a) an anti-c-met antibody (e.g., onartuzumab), wherein the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL; (b) a histidine acetate buffer at pH 5.0-5.4, wherein the histidine acetate buffer is at a concentration between about 1 mM and about 20 mM; (c) sucrose, wherein the sucrose is at a concentration between about 100 mM to about 150 mM; and (d) a polysorbate, wherein the polysorbate concentration is greater than 0.02% w/v.
an anti-c-met antibody e.g., onartuzumab
the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL
a histidine acetate buffer at pH 5.0-5.4 wherein the histidine acetate buffer is at a concentration between about 1 mM and about 20 m
the pathological condition is cancer.
the cancer is non-small cell lung cancer (NSCLC), glioblastoma, pancreatic cancer, sarcoma, renal cell carcinoma, hepatocellular carcinoma, gastric cancer, colorectal cancer, or breast cancer.
NSCLC non-small cell lung cancer
glioblastoma glioblastoma
pancreatic cancer glioblastoma
sarcoma glioblastoma
renal cell carcinoma hepatocellular carcinoma
gastric cancer colorectal cancer
colorectal cancer colorectal cancer
breast cancer or breast cancer.
the cancer is stage IIIb and/or stage IV cancer.
the cancer is locally advanced or metastatic cancer.
the therapy is second line or third line therapy (e.g., second line or third line NSCLC therapy).
Dysregulation of c-met activation (and thus signaling) can result from a number of cellular changes, including, for example, overexpression of HGF (c-met's cognate ligand) and/or c-met itself.
the cancer is EGFR mutant.
the cancer is EGFR wild-type.
the cancer is c-met positive (expresses high levels of c-met, for example, by IHC).
the pharmaceutical formulation comprises (a) an anti-c-met antibody (e.g., onartuzumab), wherein the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL; (b) a histidine acetate buffer at pH 5.0-5.4, wherein the histidine acetate buffer is at a concentration between about 1 mM and about 20 mM; (c) sucrose, wherein the sucrose is at a concentration between about 100 mM to about 150 mM; and (d) polysorbate 20, wherein the polysorbate 20 concentration is greater than 0.02% w/v.
an anti-c-met antibody e.g., onartuzumab
the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL
a histidine acetate buffer at pH 5.0-5.4 wherein the histidine acetate buffer is at a concentration between about 1 mM and about 20 mM
a pharmaceutical formulation described herein e.g., upon dilution (e.g., a diluted pharmaceutical formulation described herein)) comprising an anti-c-met antibody thereby causing an inhibition of growth of said cell.
the growth of said cell is at least in part dependent upon a growth potentiating effect of c-met or hepatocyte growth factor, or both.
the cell is contacted by HGF expressed by a different cell (e.g., through a paracrine effect).
the pharmaceutical formulation comprises (a) an anti-c-met antibody (e.g., onartuzumab), wherein the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL; (b) a histidine acetate buffer at pH 5.0-5.4, wherein the histidine acetate buffer is at a concentration between about 1 mM and about 20 mM; (c) sucrose, wherein the sucrose is at a concentration between about 100 mM to about 150 mM; and (d) polysorbate 20, wherein the polysorbate 20 concentration is greater than 0.02% w/v.
an anti-c-met antibody e.g., onartuzumab
the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL
a histidine acetate buffer at pH 5.0-5.4 wherein the histidine acetate buffer is at a concentration between about 1 mM and about 20 mM
a pharmaceutical formulation comprising (a) an anti-c-met antibody (e.g., onartuzumab), wherein the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL; (b) a histidine acetate buffer at pH 5.0-5.4, wherein the histidine acetate buffer is at a concentration between about 1 mM and about 20 mM; (c) sucrose, wherein the sucrose is at a concentration between about 100 mM to about 150 mM; and (d) polysorbate 20, wherein the polysorbate 20 concentration is greater than 0.02% w/v (e.g., upon dilution to about any of 0.75, 1, or 1.25 mg/mL (e.g., a diluted pharmaceutical formulation described herein)).
an anti-c-met antibody e.g., onartuzumab
the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL
the pharmaceutical formulation comprises (a) an anti-c-met antibody (e.g., onartuzumab), wherein the anti-c-met antibody is present at a concentration of about 60 mg/mL; (b) a histidine acetate buffer at pH 5.4, wherein the histidine acetate buffer is at a concentration of about 10 mM; (c) sucrose, wherein the sucrose is at a concentration of about 120 mM; and (d) polysorbate 20, wherein the polysorbate 20 concentration is about 0.04% w/v.
an anti-c-met antibody e.g., onartuzumab
the anti-c-met antibody is present at a concentration of about 60 mg/mL
a histidine acetate buffer at pH 5.4 wherein the histidine acetate buffer is at a concentration of about 10 mM
sucrose wherein the sucrose is at a concentration of about 120 mM
polysorbate 20 concentration is about 0.04% w/v.
the cancer is non-small cell lung cancer (NSCLC), glioblastoma, pancreatic cancer, sarcoma, renal cell carcinoma, hepatocellular carcinoma, gastric cancer, colorectal cancer, or breast cancer.
NSCLC non-small cell lung cancer
the cancer is stage IIIb and/or stage IV cancer.
the cancer is locally advanced or metastatic cancer.
the therapy is second line or third line therapy (e.g., second line or third line NSCLC therapy).
the cancer is EGFR mutant.
the cancer is EGFR wild-type.
the cancer is c-met positive (expresses high levels of c-met, for example, by IHC).
the dose of anti-c-met antibody is about 15 mg/kg. In some embodiments, the dose of anti-c-met antibody is about 15 mg/kg administered day one of a 21 day cycle. In some embodiments, the dose of anti-c-met antibody is about 10 mg/kg. In some embodiments, the dose of anti-c-met antibody is about 10 mg/kg administered on day 1 and 15 of a 28 day cycle.
Methods described herein can be used to affect any suitable pathological state, for example, cells and/or tissues associated with dysregulation of the HGF/c-met signaling pathway.
a cell that is targeted in a method described herein is a cancer cell.
a cancer cell can be one selected from the group consisting of a breast cancer cell, a colorectal cancer cell, a lung cancer cell, a papillary carcinoma cell (e.g., of the thyroid gland), a colon cancer cell, a pancreatic cancer cell, an ovarian cancer cell, a cervical cancer cell, a central nervous system cancer cell, an osteogenic sarcoma cell, a renal carcinoma cell, a hepatocellular carcinoma cell, a bladder cancer cell, a gastric carcinoma cell, a head and neck squamous carcinoma cell, a melanoma cell and a leukemia cell.
a cell that is targeted in a method described herein is a hyperproliferative and/or hyperplastic cell.
a cell that is targeted in a method described herein is a dysplastic cell.
a cell that is targeted in a method described herein is a metastatic cell.
the method further comprises additional treatment steps.
the method further comprises a step wherein a targeted cell and/or tissue (e.g., a cancer cell) is exposed to radiation treatment or a second therapeutic agent (e.g., chemotherapeutic agent).
a targeted cell and/or tissue e.g., a cancer cell
a second therapeutic agent e.g., chemotherapeutic agent
a pharmaceutical formulation comprising (a) an anti-c-met antibody (e.g., onartuzumab), wherein the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL; (b) a histidine acetate buffer at pH 5.0-5.4, wherein the histidine acetate buffer is at a concentration between about 1 mM and about 20 mM; (c) sucrose, wherein the sucrose is at a concentration between about 100 mM to about 150 mM; and (d) polysorbate 20, wherein the polysorbate 20 concentration is greater than 0.02% w/v (e.g., upon dilution to about any of 0.75, 1, or 1.25 mg/mL (e.g., a diluted pharmaceutical formulation described herein)) and (ii) a second therapeutic agent.
the second therapeutic agent is an EGFR inhibitor (e.g.,
the method further comprises administering an effective amount of a second therapeutic agent.
the dose of anti-c-met antibody is about 15 mg/kg. In some embodiments, the dose of anti-c-met antibody is about 10 mg/kg.
the second therapeutic agent is an EGFR inhibitor.
the EGFR inhibitor is erlotinib (N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine).
the dose of anti-c-met antibody is about 15 mg/kg administered day one of a 21 day cycle.
a pharmaceutical formulation comprising (a) an anti-c-met antibody (e.g., onartuzumab), wherein the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL; (b) a histidine acetate buffer at pH 5.0-5.4, wherein the histidine acetate buffer is at a concentration between about 1 mM and about 20 mM; (c) sucrose, wherein the sucrose is at a concentration between about 100 mM to about 150 mM; and (d) polysorbate 20, wherein the polysorbate 20 concentration is greater than 0.02% w/v (e.g., upon dilution to about any of 0.75, 1, or 1.25 mg/mL (e.g., a diluted pharmaceutical formulation described herein)), wherein the anti-c-met antibody is administered at a dose of 15 mg/kg every three weeks; and
the second therapeutic agent is a taxane (e.g., paclitaxel).
the cancer is breast cancer.
the breast cancer is an ER-negative, PR-negative, and HER2-negative (ER-, PR-, and HER2-; or triple-negative) metastatic breast cancer.
the dose of anti-c-met antibody is about 10 mg/kg. on day 1 and day 15 of a 28-day cycle.
a pharmaceutical formulation comprising (a) an anti-c-met antibody (e.g., onartuzumab), wherein the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL; (b) a histidine acetate buffer at pH 5.0-5.4, wherein the histidine acetate buffer is at a concentration between about 1 mM and about 20 mM; (c) sucrose, wherein the sucrose is at a concentration between about 100 mM to about 150 mM; and (d) polysorbate 20, wherein the polysorbate 20 concentration is greater than 0.02% w/v (e.g., upon dilution to about any of 0.75, 1, or 1.25 mg/mL (e.g., a diluted pharmaceutical formulation described herein)), wherein the anti-c-met antibody is administered at a dose of 10 mg/kg on day 1 and day 15
an anti-c-met antibody e.g., onartuzumab
the method increases survival of the patient, decreases the patient's risk of cancer recurrence and/or to increases the patient's likelihood of survival.
the method further comprises administration of an anti-VEGF antibody (e.g., bevacizumab).
a pharmaceutical formulation comprising (a) an anti-c-met antibody (e.g., onartuzumab), wherein the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL; (b) a histidine acetate buffer at pH 5.0-5.4, wherein the histidine acetate buffer is at a concentration between about 1 mM and about 20 mM; (c) sucrose, wherein the sucrose is at a concentration between about 100 mM to about 150 mM; and (d) polysorbate 20, wherein the polysorbate 20 concentration is greater than 0.02% w/v (e.g., upon dilution to about any of 0.75, 1, or 1.25 mg/mL (e.g., a diluted pharmaceutical formulation described herein)), wherein the anti-c-met antibody is administered at a dose of 10 mg/kg on day 1 and day 15
an anti-c-met antibody e.g., onartuzumab
composition comprising the anti-c-met antibody can be used either alone or in combination with other agents in a therapy.
pharmaceutical formulation comprising the anti-c-met antibody may be co-administered with a second therapeutic agent (e.g., another antibody, chemotherapeutic agent(s) (including cocktails of chemotherapeutic agents), other cytotoxic agent(s), anti-angiogenic agent(s), cytokines, and/or growth inhibitory agent(s)).
a second therapeutic agent e.g., another antibody, chemotherapeutic agent(s) (including cocktails of chemotherapeutic agents), other cytotoxic agent(s), anti-angiogenic agent(s), cytokines, and/or growth inhibitory agent(s)
the second therapeutic agent is administered concurrently or sequentially.
the second therapeutic agent can be administered separately from the pharmaceutical formulation comprising the anti-c-met antibody, but as a part of the same treatment regimen.
anti-c-met antibody of the pharmaceutical formulation inhibits tumor growth
pharmaceutical formulation comprising the anti-c-met antibody may be combined with an EGFR inhibitor, an anti-VEGF antibody and/or anti-ErbB antibodies in a treatment scheme, e.g. in treating any of the diseases described herein, including colorectal cancer, metastatic breast cancer and kidney cancer.
Such combined therapies noted above encompass combined administration (where two or more agents are included in the same or separate formulations), simultaneously, and separate administration, in which case, administration of the pharmaceutical formulation can occur prior to, and/or following, administration of the additional therapeutic agent and/or adjuvant.
the method comprises targeting a cell wherein c-met or hepatocyte growth factor, or both, is more abundantly expressed by said cell (e.g., a cancer cell) as compared to a normal cell of the same tissue origin.
a c-met-expressing cell can be regulated by HGF from a variety of sources, i.e. in an autocrine or paracrine manner.
C-met activation and/or signaling can also occur independent of ligand.
c-met activation in a targeted cell occurs independent of ligand.
the pharmaceutical formulation comprising the anti-c-met antibody can be administered to a human subject for therapeutic purposes.
pharmaceutical formulation comprising the anti-c-met antibody can be administered to a non-human mammal expressing an antigen with which the immunoglobulin cross-reacts (e.g., a primate, pig or mouse) for veterinary purposes or as an animal model of human disease.
the pharmaceutical formulation comprising the anti-c-met antibody can be used to treat, inhibit, delay progression of, prevent/delay recurrence of, ameliorate, or prevent diseases, disorders or conditions associated with abnormal expression and/or activity of one or more antigen molecules, including but not limited to malignant and benign tumors; non-leukemias and lymphoid malignancies; neuronal, glial, astrocytal, hypothalamic and other glandular, macrophagal, epithelial, stromal and blastocoelic disorders; and inflammatory, angiogenic and immunologic disorders.
a pharmaceutical formulation comprising an immunoconjugate comprising the anti-c-met antibody conjugated with a cytotoxic agent is administered to the patient.
the immunoconjugate and/or antigen to which it is bound is/are internalized by the cell, resulting in increased therapeutic efficacy of the immunoconjugate in killing the target cell to which it binds.
the cytotoxic agent targets or interferes with nucleic acid in the target cell.
the pharmaceutical formulation comprising the anti-c-met antibody (and any additional therapeutic agent) can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration.
Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
the pharmaceutical formulation is administered intravenously. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic.
Various dosing schedules including, but not limited to, single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.
compositions comprising the anti-c-met antibody are dosed and administered in a fashion consistent with good medical practice.
Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
the pharmaceutical formulation comprising the anti-c-met antibody need not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question.
the effective amount of such other agents depends on the amount of antibodies present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as used hereinbefore or about from 1 to 99% of the heretofore employed dosages described herein, or any dosage and by any route that is empirically/clinically determined to be appropriate.
the appropriate dosage of the anti-c-met antibody in the pharmaceutical formulation (when used alone or in combination with one or more additional therapeutic agents) will depend on the type of disease to be treated, the type of antibody, the severity and course of the disease, whether the anti-c-met antibody in the pharmaceutical formulation is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the anti-c-met antibody, and the discretion of the attending physician.
the pharmaceutical formulation comprising the anti-c-met antibody is suitably administered to the patient at one time or over a series of treatments.
the dose of anti-c-met antibody is about 15 mg/kg. In some embodiments, the dose of anti-c-met antibody is about 15 mg/kg administered day one of a 21 day cycle. In some embodiments, the dose of anti-c-met antibody is about 10 mg/kg. In some embodiments, the dose of anti-c-met antibody is about 10 mg/kg administered on day 1 and 15 of a 28 day cycle.
Doses may be administered intermittently, e.g. about any of every week, every two weeks, every three weeks, or every four weeks.
the treatment would generally be sustained until a desired suppression of disease symptoms occurs.
other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.
Article of manufacture comprising the pharmaceutical formulation comprising an anti-c-met antibody described herein for the treatment, prevention and/or diagnosis of the disorders described above is provided.
the article of manufacture comprises a container and a label or package insert on or associated with the container.
Suitable containers include, for example, bottles, vials, syringes, IV solution bags etc.
the containers may be formed from a variety of materials such as glass or plastic.
the container holds the pharmaceutical formulation comprising the anti-c-met antibody which is by itself or when combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
articles of manufacture and kits comprising a container with a pharmaceutical formulation comprising (a) an anti-c-met antibody (e.g., onartuzumab), wherein the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL; (b) a histidine acetate buffer at pH 5.0-5.4, wherein the histidine acetate buffer is at a concentration between about 1 mM and about 20 mM; (c) sucrose, wherein the sucrose is at a concentration between about 100 mM to about 150 mM; and (d) polysorbate 20, wherein the polysorbate 20 concentration is greater than 0.02% w/v contained therein.
an anti-c-met antibody e.g., onartuzumab
a histidine acetate buffer at pH 5.0-5.4, wherein the histidine acetate buffer is at a concentration between about 1 mM and about 20 mM
sucrose wherein the sucrose is at
the pharmaceutical formulation comprises (a) an anti-c-met antibody (e.g., onartuzumab), wherein the anti-c-met antibody is present at a concentration of about 60 mg/mL; (b) a histidine acetate buffer at pH 5.4, wherein the histidine acetate buffer is at a concentration of about 10 mM; (c) sucrose, wherein the sucrose is at a concentration of about 120 mM; and (d) a polysorbate, wherein the polysorbate concentration is about 0.04% w/v.
an anti-c-met antibody e.g., onartuzumab
the anti-c-met antibody is present at a concentration of about 60 mg/mL
a histidine acetate buffer at pH 5.4 wherein the histidine acetate buffer is at a concentration of about 10 mM
sucrose wherein the sucrose is at a concentration of about 120 mM
a polysorbate wherein the polysorbate concentration is about
the cancer is non-small cell lung cancer (NSCLC), glioblastoma, pancreatic cancer, sarcoma, renal cell carcinoma, gastric cancer, colorectal cancer, or breast cancer.
NSCLC non-small cell lung cancer
the cancer is stage IIIb and/or stage IV cancer.
the cancer is locally advanced or metastatic cancer.
the therapy is second line or third line therapy (e.g., second line or third line NSCLC therapy).
the cancer is EGFR mutant.
the cancer is EGFR wild-type.
the cancer is c-met positive (expresses high levels of c-met, for example, by immunohistochemistry).
the dose of anti-c-met antibody is about 15 mg/kg. In some embodiments, the dose of anti-c-met antibody is about 15 mg/kg administered day one of a 21 day cycle. In some embodiments, the dose of anti-c-met antibody is about 10 mg/kg. In some embodiments, the dose of anti-c-met antibody is about 10 mg/kg administered on day 1 and 15 of a 28 day cycle.
the article of manufacture in this embodiment may further comprise a package insert indicating that the first and second antibody compositions can be used to treat a particular condition, e.g. cancer.
the cancer is non-small cell lung cancer (NSCLC), glioblastoma, pancreatic cancer, sarcoma, renal cell carcinoma, gastric cancer, colorectal cancer, or breast cancer.
the cancer is stage IIIb and/or stage IV.
the cancer is locally advanced or metastatic cancer.
the therapy is second line or third line therapy (e.g., second line or third line NSCLC therapy).
the cancer is EGFR mutant.
the cancer is EGFR wild-type.
the cancer is c-met positive (expresses high levels of c-met, for example, by immunohistochemistry).
the dose of anti-c-met antibody is about 15 mg/kg. In some embodiments, the dose of anti-c-met antibody is about 15 mg/kg administered day one of a 21 day cycle.
the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
BWFI bacteriostatic water for injection
phosphate-buffered saline such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution.
BWFI bacteriostatic water for injection
phosphate-buffered saline such as phosphate-buffered saline, Ringer's solution and dextrose solution.
dextrose solution such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer'
the article of manufacture may comprise (a) a first container with a pharmaceutical formulation described herein comprising an anti-c-met antibody contained therein; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic agent.
the article of manufacture may comprise (i) a first container with a pharmaceutical formulation comprising (a) an anti-c-met antibody (e.g., onartuzumab), wherein the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL; (b) a histidine acetate buffer at pH 5.0-5.4, wherein the histidine acetate buffer is at a concentration between about 1 mM and about 20 mM; (c) sucrose, wherein the sucrose is at a concentration between about 100 mM to about 150 mM; and (d) polysorbate 20, wherein the polysorbate 20 concentration is greater than 0.02% w/v; and (ii) a second container with a composition contained therein, wherein the composition comprises a second therapeutic agent.
an anti-c-met antibody e.g., onartuzumab
the anti-c-met antibody is present at a concentration between about 50 mg/mL and about 75 mg/mL
the second therapeutic agent is an EGFR inhibitor.
the EGFR inhibitor is erlotinib (N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine).
the article of manufacture comprises instructions for administration of about 15 mg/kg administered day one of a 21 day cycle of anti-c-met antibody formulation and 150 mg, each day of a three week cycle of erlotinib.
the article of manufacture comprises instructions for the treatment of cancer (e.g., NSCLC).
the second therapeutic agent is a taxane (e.g., paclitaxel).
the article of manufacture comprises instructions for administration of about 10 mg/kg. on day 1 and day 15 of a 28-day cycle of the anti-c-met antibody formulation and 90 mg/m 2 by IV infusion on day 1, day 8, and day 15 of the 28-day cycle of paclitaxel.
the article of manufacture comprises a third container with a composition contained therein, wherein the composition comprises a third therapeutic agent, wherein the third therapeutic agent is an anti-VEGF antibody (e.g., bevacizumab).
the article of manufacture comprises instructions for administration of about 10 mg/kg.
the article of manufacture comprises instructions for the treatment of cancer.
the cancer is breast cancer (e.g., ER-negative, PR-negative, and HER2-negative (ER-, PR-, and HER2-; or triple-negative) metastatic breast cancer).
the method increases survival of the patient, decreases the patient's risk of cancer recurrence and/or to increases the patient's likelihood of survival.
any of the above articles of manufacture may include an immunoconjugate of the anti-c-met antibody disclosed herein in place or in addition to the anti-c-met antibody.
a pharmaceutical formulation comprising:
the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6).
the anti-c-met antibody comprises (a) a heavy chain variable domain comprising the sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDT RFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTV SS (SEQ ID NO:19) and (b) a light chain variable domain comprising the sequence: DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTR ESGVPSRFSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKR (SEQ ID NO:20).
the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.
the first and second Fc polypeptides form a Fc region that increases stability of said antibody fragment compared to a Fab molecule comprising said antigen binding arm. 6.
the anti-c-met antibody comprises (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO:19, a CH1 sequence, and a first Fc polypeptide and (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO:20 and CL1 sequence.
the anti-c-met antibody further comprises (c) a third polypeptide comprising a second Fc polypeptide.
the first Fc polypeptide comprises the Fc sequence depicted in FIG. 2 (SEQ ID NO: 17) and the second Fc polypeptide comprises the Fc sequence depicted in FIG.
a diluent e.g. 0.9% NaCl
26. A method of inhibiting c-met activated cell proliferation, said method comprising contacting a cell or tissue with an effective amount of the pharmaceutical formulation of any one of embodiments 1-25.
27. A method of modulating a disease associated with dysregulation of the HGF/c-met signaling axis, said method comprising administering to a subject an effective amount of the pharmaceutical formulation of any one of embodiments 1-25. 28.
a method of treating a subject having a proliferative disorder comprising administering to the subject an effective amount of the pharmaceutical formulation of any one of embodiments 1-25. 29.
the method of embodiment 28, wherein the proliferative disorder is cancer.
the cancer is lung cancer (e.g., non-small cell lung cancer (NSCLC)), glioblastoma, pancreatic cancer, sarcoma, renal cell carcinoma, hepatocellular carcinoma, gastric cancer, colorectal cancer, and/or breast cancer.
NSCLC non-small cell lung cancer
glioblastoma glioblastoma
pancreatic cancer glioblastoma
sarcoma glioblastoma
pancreatic cancer glioblastoma
sarcoma glioblastoma
pancreatic cancer glioblastoma
sarcoma glioblastoma
renal cell carcinoma hepatocellular carcinoma
gastric cancer color
the viscosity and stability of onartuzumab at various concentrations (20-100 mg/mL) was evaluated in different buffers: a) 10 mM histidine-acetate, 0.02% polysorbate 20, and 120 mM trehalose, b) 10 mM histidine-succinate, 0.02% polysorbate 20, and 120 mM trehalose, and c) 200 mM arginine-succinate and 0.02% polysorbate 20.
the formulation including arginine succinate had faster aggregate formation at accelerated temperatures (data not shown). The viscosity was acceptable for all formulations evaluated.
HMWS high molecule weight species
Polysorbate is utilized in polypeptide formulations to minimize adsorption to surfaces and reduce the air-liquid interfacial surface tension and thus the rate of protein denaturation. Loss of polysorbate in a pharmaceutical formulation can result in instability of the formulation. Further, polysorbates can be degraded by oxidation and hydrolysis which can lead to a decrease in the apparent concentration of polysorbate in the pharmaceutical formulation over long shelf life. These polysorbate degradants are less surface-active than nondegraded polysorbate and hence the chemical and physical stability of the pharmaceutical formulation may be compromised. Further, some polysorbate degradants are insoluble and may form particles if they are not solubilized by intact polysorbate, i.e., if the ratio of degraded polysorbate 20: intact polysorbate 20 is too high.
the rate and extent of degradation of polysorbate was evaluated in an onartuzumab formulation including 60 mg/mL of onartuzumab in 10 mM histidine acetate, 120 mM sucrose, 0.02% polysorbate 20, pH 5.4 at 40° C. over time.
the concentration of polysorbate 20 was assessed with an assay based on the retention of polysorbate by a mixed-mode ion-exchange column and subsequent elution with a step gradient. Detection was performed using an evaporative light scattering detector (ELSD).
the rate of degradation and the ratio of degraded polysorbate 20:intact polysorbate 20 was higher than expected in the onartuzumab formulation at 40° C. over time. The higher than expected rate of degradation and the ratio of degraded polysorbate 20:intact polysorbate 20 could result in instability of the onartuzumab formulation and particulate formation after extended storage.
the percentage of polysorbate 20 was increased in the onartuzumab formulation and the rate and extent of degradation of polysorbate was evaluated in onartuzumab formulations: a) 60 mg/mL of onartuzumab in 10 mM histidine acetate, 120 mM sucrose, 0.02% polysorbate 20, pH 5.4 and b) 60 mg/mL onartuzumab in 10 mM histidine acetate, 120 mM sucrose, 0.04% polysorbate 20, pH 5.4 at 40° C. over time as described above. Surprisingly, as shown in FIG.
the increase in polysorbate 20 concentration not only increased the overall levels of polysorbate 20 available to stabilize the onartuzumab formulation, but further decreased the ratio of degraded polysorbate 20:intact polysorbate 20 at 40° C. over time, thereby further increasing the stability of the onartuzumab formulation after extended storage.
the onartuzumab formulation Prior to administration, the onartuzumab formulation is diluted with a diluent (e.g., saline solution) for intravenous infusion. Upon dilution, the polysorbate 20 concentration is significantly reduced, and the stability of the onartuzumab in the formulation could be compromised, for example, by polypeptide aggregation as evidenced by % HMWS, when the diluted onartuzumab formulation (e.g., IV bag and/or IV administration set) is agitated (e.g., during transportation). As previously discussed, aggregation of the monovalent onartuzumab (formation of multimer and oligomers) and/or failure to maintain monovalent structure could lead to an undesirable agonistic effect.
a diluent e.g., saline solution
the polysorbate 20 concentration is significantly reduced, and the stability of the onartuzumab in the formulation could be compromised, for example, by polypeptide aggregation
onartuzumab formulations a) 60 mg/mL of onartuzumab in 10 mM histidine acetate, 120 mM trehalose, 0.02% polysorbate 20, pH 5.4 and b) 60 mg/mL onartuzumab in 10 mM histidine acetate, 120 mM sucrose, 0.04% polysorbate 20, pH 5.4, were diluted to 1 mg/mL in IV bags (PVC) with 0.9% NaCl. The bags were agitated (orbital shaker, 100 rpm) at room temperature for formulation (a) and 30° C. for formulation (b).

US13/538,901 2011-06-30 2012-06-29 Anti-c-met antibody formulations Abandoned US20130004484A1 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
US13/538,901 US20130004484A1 (en)	2011-06-30	2012-06-29	Anti-c-met antibody formulations
US14/534,085 US9487589B2 (en)	2011-06-30	2014-11-05	Anti-c-met-antibody formulations

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161503513P	2011-06-30	2011-06-30
US13/538,901 US20130004484A1 (en)	2011-06-30	2012-06-29	Anti-c-met antibody formulations

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
US14/534,085 Continuation US9487589B2 (en)	2011-06-30	2014-11-05	Anti-c-met-antibody formulations

Publications (1)

Publication Number	Publication Date
US20130004484A1 true US20130004484A1 (en)	2013-01-03

Family

ID=46513859

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
US13/538,901 Abandoned US20130004484A1 (en)	2011-06-30	2012-06-29	Anti-c-met antibody formulations
US14/534,085 Expired - Fee Related US9487589B2 (en)	2011-06-30	2014-11-05	Anti-c-met-antibody formulations

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
US14/534,085 Expired - Fee Related US9487589B2 (en)	2011-06-30	2014-11-05	Anti-c-met-antibody formulations

Country Status (15)

Country	Link
US (2)	US20130004484A1 (zh)
EP (1)	EP2726098A1 (zh)
JP (1)	JP2014522843A (zh)
KR (1)	KR20140045440A (zh)
CN (2)	CN103781493A (zh)
AR (1)	AR086823A1 (zh)
AU (1)	AU2012275233A1 (zh)
BR (1)	BR112013030472A2 (zh)
CA (1)	CA2835242A1 (zh)
IL (1)	IL229233A0 (zh)
MX (1)	MX2013014687A (zh)
RU (1)	RU2013155695A (zh)
SG (1)	SG194932A1 (zh)
TW (1)	TW201306866A (zh)
WO (1)	WO2013003680A1 (zh)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130078232A1 (en) *	2010-03-22	2013-03-28	Genentech, Inc.	Compositions and methods useful for stabilizing protein-containing formulations
US20150258194A1 (en) *	2012-08-31	2015-09-17	Vib Vzw	Modulating transendothelial migration and recruitment of granulocytes by modulating c-met pathway
WO2016073915A1 (en) *	2014-11-07	2016-05-12	Novartis Ag	Stable protein solution formulation containing high concentration of an anti-vegf antibody
JP2016534062A (ja) *	2013-10-25	2016-11-04	バイエルファーマアクチエンゲゼルシャフト	新規な安定製剤
US9487589B2 (en)	2011-06-30	2016-11-08	Genentech, Inc.	Anti-c-met-antibody formulations
US9517266B2 (en)	2013-03-29	2016-12-13	Samsung Electronics Co., Ltd.	Liquid formulation containing a protein drug
US9827291B2 (en)	2013-01-30	2017-11-28	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US9828415B2 (en)	2013-01-30	2017-11-28	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US9834586B2 (en)	2014-07-30	2017-12-05	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US9920118B2 (en)	2014-10-31	2018-03-20	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US10174119B2 (en)	2016-03-31	2019-01-08	Ngm Biopharmaceuticals, Inc.	Binding proteins and methods of use thereof
US10195250B2 (en)	2012-03-27	2019-02-05	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US10227416B2 (en)	2009-11-05	2019-03-12	Genentech, Inc.	Methods and composition for secretion of heterologous polypeptides
US10240207B2 (en)	2014-03-24	2019-03-26	Genentech, Inc.	Cancer treatment with c-met antagonists and correlation of the latter with HGF expression
TWI735486B (zh) *	2015-12-10	2021-08-11	日商新力股份有限公司	收訊裝置、及資料處理方法
US11634485B2 (en)	2019-02-18	2023-04-25	Eli Lilly And Company	Therapeutic antibody formulation
US11884734B2 (en)	2015-03-16	2024-01-30	Celldex Therapeutics, Inc.	Anti-MET antibodies and methods of use thereof
US11945859B2 (en)	2018-12-18	2024-04-02	Novartis Ag	Protein solution formulation containing high concentration of an anti-VEGF antibody

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2771031B1 (en)	2011-10-28	2018-04-18	Prothena Biosciences Limited	Humanized antibodies that recognize alpha-synuclein
NZ629296A (en)	2012-01-27	2016-06-24	Prothena Biosciences Ltd	Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk)	2012-10-08	2019-01-25	Протена Біосаєнсиз Лімітед	Антитіло, що розпізнає альфа-синуклеїн
SG11201506499YA (en)	2013-03-15	2015-09-29	Glaxosmithkline Ip No 2 Ltd	Low concentration antibody formulations
US10513555B2 (en) *	2013-07-04	2019-12-24	Prothena Biosciences Limited	Antibody formulations and methods
MA39746A (fr)	2014-03-14	2021-04-28	Hoffmann La Roche	Compositions de sécrétion de polypeptides hétérologues et procédés associés
CA3003759A1 (en) *	2015-11-03	2017-05-11	Merck Patent Gmbh	Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
TWI782930B (zh)	2016-11-16	2022-11-11	美商再生元醫藥公司	抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US20200129633A1 (en)	2017-06-06	2020-04-30	Jiangsu Hengrui Medicine Co., Ltd.	Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof
CN110144325A (zh) *	2018-02-12	2019-08-20	深圳宾德生物技术有限公司	一种靶向性t淋巴细胞及其制备方法和应用
CN110684113A (zh) *	2018-07-06	2020-01-14	复旦大学	一种抗PD-1抗原和抗c-Met抗原的双特异性抗体及其构建方法
CN112239506B (zh) *	2019-07-16	2023-09-26	复旦大学	一种抗PD-1及c-Met抗原的小分子双特异性抗体Diabody
US11896682B2 (en)	2019-09-16	2024-02-13	Regeneron Pharmaceuticals, Inc.	Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
AU2022309554A1 (en)	2021-07-14	2024-02-22	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010045345A2 (en) *	2008-10-17	2010-04-22	Genentech, Inc.	Treatment method
US20110287003A1 (en) *	2010-05-14	2011-11-24	Genentech, Inc.	Treatment methods

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4342566A (en)	1980-02-22	1982-08-03	Scripps Clinic & Research Foundation	Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8318575D0 (en)	1983-07-08	1983-08-10	Cobbold S P	Antibody preparations
US5169939A (en)	1985-05-21	1992-12-08	Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College	Chimeric antibodies
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US5770701A (en)	1987-10-30	1998-06-23	American Cyanamid Company	Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en)	1987-10-30	1997-02-25	American Cyanamid Company	Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
KR0184860B1 (ko)	1988-11-11	1999-04-01	메디칼 리써어치 카운실	단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2026147C (en)	1989-10-25	2006-02-07	Ravi J. Chari	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5648273A (en)	1989-12-27	1997-07-15	The United States Of America, As Represented By The Department Of Health And Human Services	Hepatic growth factor receptor is the MET proto-oncogene
US5871959A (en)	1989-12-27	1999-02-16	The United States Of America As Represented By The Department Of Health And Human Services	Method of producing hepatocycte growth factor/scatter factor and related cell lines
US5362716A (en)	1989-12-27	1994-11-08	The United States Of America As Represented By The Department Of Health And Human Services	Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
CA2091700C (en)	1990-09-14	2002-11-19	Jeffrey S. Rubin	A non-mitogenic competitive hgf antagonist
US5968509A (en)	1990-10-05	1999-10-19	Btp International Limited	Antibodies with binding affinity for the CD3 antigen
US5264365A (en)	1990-11-09	1993-11-23	Board Of Regents, The University Of Texas System	Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en)	1990-11-09	1996-04-16	Board Of Regents, The University Of Texas System	Bacterial host strains for producing proteolytically sensitive polypeptides
ES2113940T3 (es)	1990-12-03	1998-05-16	Genentech Inc	Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
EP0584125B1 (en)	1991-05-10	1997-07-16	PHARMACIA & UPJOHN S.p.A.	Truncated forms of the hepatocyte growth factor (hgf) receptor
US5227158A (en)	1991-06-10	1993-07-13	Genentech, Inc.	Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
ES2206447T3 (es)	1991-06-14	2004-05-16	Genentech, Inc.	Anticuerpo humanizado para heregulina.
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
US7018809B1 (en)	1991-09-19	2006-03-28	Genentech, Inc.	Expression of functional antibody fragments
US5587458A (en)	1991-10-07	1996-12-24	Aronex Pharmaceuticals, Inc.	Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
JPH07501451A (ja)	1991-11-25	1995-02-16	エンゾン・インコーポレイテッド	多価抗原結合タンパク質
AU675929B2 (en)	1992-02-06	1997-02-27	Curis, Inc.	Biosynthetic binding protein for cancer marker
WO1993022332A2 (en)	1992-04-24	1993-11-11	Board Of Regents, The University Of Texas System	Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5316921A (en)	1992-05-18	1994-05-31	Genentech, Inc.	Single-chain hepatocyte growth factor variants
EP0642585B1 (en)	1992-05-18	2005-12-28	Genentech, Inc.	Activation of oligomerizing receptors by using fused receptor ligands
ATE222603T1 (de)	1992-05-18	2002-09-15	Genentech Inc	Hepatozytwachstumfaktor variante
US5328837A (en)	1992-05-18	1994-07-12	Genentech, Inc.	Hepatocyte growth factor protease domain variants
DK0662130T3 (da)	1992-09-18	1998-08-10	Us Gov Health & Human Serv	Fremgangsmåde til fremstilling af hepatocytvækstfaktor og en cellelinje
CA2149329C (en)	1992-11-13	2008-07-15	Darrell R. Anderson	Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5635483A (en)	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en)	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
GB2294267B (en)	1993-06-03	1996-11-20	Therapeutic Antibodies Inc	Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies
JPH08511420A (ja)	1993-06-16	1996-12-03	セルテック・セラピューテイクス・リミテッド	抗体
RU2146262C1 (ru)	1993-06-30	2000-03-10	Фармация Энд Апджон С.П.А.	Пептиды, способ их получения, фармацевтическая композиция и способ ее получения
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en)	1994-11-03	1998-08-04	Genentech, Inc.	Process for bacterial production of polypeptides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US6121022A (en)	1995-04-14	2000-09-19	Genentech, Inc.	Altered polypeptides with increased half-life
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
US5686292A (en)	1995-06-02	1997-11-11	Genentech, Inc.	Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en)	1995-06-02	1997-07-08	Genentech, Inc.	Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6214344B1 (en)	1995-06-02	2001-04-10	Genetech, Inc.	Hepatocyte growth factor receptor antagonists and uses thereof
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6685940B2 (en)	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
AU2660397A (en)	1996-04-05	1997-10-29	Board Of Regents, The University Of Texas System	Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
EP0973804B1 (en)	1997-04-07	2006-12-27	Genentech, Inc.	Anti-vegf antibodies
US6083715A (en)	1997-06-09	2000-07-04	Board Of Regents, The University Of Texas System	Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
DE69830315T2 (de)	1997-06-24	2006-02-02	Genentech Inc., San Francisco	Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US5994511A (en)	1997-07-02	1999-11-30	Genentech, Inc.	Anti-IgE antibodies and methods of improving polypeptides
US6040498A (en)	1998-08-11	2000-03-21	North Caroline State University	Genetically engineered duckweed
ATE419009T1 (de)	1997-10-31	2009-01-15	Genentech Inc	Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6610833B1 (en)	1997-11-24	2003-08-26	The Institute For Human Genetics And Biochemistry	Monoclonal human natural antibodies
ATE531812T1 (de)	1997-12-05	2011-11-15	Scripps Research Inst	Humanisierung von nager-antikörpern
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
ATE375365T1 (de)	1998-04-02	2007-10-15	Genentech Inc	Antikörper varianten und fragmente davon
AU3657899A (en)	1998-04-20	1999-11-08	James E. Bailey	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
DK1135498T3 (da)	1998-11-18	2008-05-26	Genentech Inc	Antistofvarianter med höjere bindingsaffinitet end forældreantistoffer
DE19858253A1 (de)	1998-12-17	2000-06-21	Aventis Pharma Gmbh	Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden
HUP0104865A3 (en)	1999-01-15	2004-07-28	Genentech Inc	Polypeptide variants with altered effector function
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
EP2275540B1 (en)	1999-04-09	2016-03-23	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
WO2000067796A1 (en)	1999-05-07	2000-11-16	Genentech, Inc.	Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
AU782626B2 (en)	1999-10-04	2005-08-18	Medicago Inc.	Method for regulating transcription of foreign genes
US7125978B1 (en)	1999-10-04	2006-10-24	Medicago Inc.	Promoter for regulating expression of foreign genes
EP1229125A4 (en)	1999-10-19	2005-06-01	Kyowa Hakko Kogyo Kk	PROCESS FOR PRODUCING A POLYPEPTIDE
AU784983B2 (en)	1999-12-15	2006-08-17	Genentech Inc.	Shotgun scanning, a combinatorial method for mapping functional protein epitopes
ATE337403T1 (de)	1999-12-24	2006-09-15	Genentech Inc	Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
AU767394C (en)	1999-12-29	2005-04-21	Immunogen, Inc.	Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
ES2528794T3 (es)	2000-04-11	2015-02-12	Genentech, Inc.	Anticuerpos multivalentes y usos de los mismos
JP2004527456A (ja)	2000-08-09	2004-09-09	イムクローンシステムズインコーポレイティド	Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
CA2424602C (en)	2000-10-06	2012-09-18	Kyowa Hakko Kogyo Co., Ltd.	Antibody composition-producing cell
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
JP3523245B1 (ja)	2000-11-30	2004-04-26	メダレックス，インコーポレーテッド	ヒト抗体作製用トランスジェニック染色体導入齧歯動物
NZ592087A (en)	2001-08-03	2012-11-30	Roche Glycart Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ES2326964T3 (es)	2001-10-25	2009-10-22	Genentech, Inc.	Composiciones de glicoproteina.
PT1441589E (pt)	2001-11-08	2012-08-13	Abbott Biotherapeutics Corp	Formulação farmacêutica líquida estável de anticorpos igg
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
AU2003236018A1 (en)	2002-04-09	2003-10-20	Kyowa Hakko Kirin Co., Ltd.	METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
CA2481837A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Production process for antibody composition
US20040110704A1 (en)	2002-04-09	2004-06-10	Kyowa Hakko Kogyo Co., Ltd.	Cells of which genome is modified
US7691568B2 (en)	2002-04-09	2010-04-06	Kyowa Hakko Kirin Co., Ltd	Antibody composition-containing medicament
ATE503829T1 (de)	2002-04-09	2011-04-15	Kyowa Hakko Kirin Co Ltd	Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
AU2003236019A1 (en)	2002-04-09	2003-10-20	Kyowa Hakko Kirin Co., Ltd.	Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
EP1513879B1 (en)	2002-06-03	2018-08-22	Genentech, Inc.	Synthetic antibody phage libraries
RS20050834A (en)	2002-08-19	2007-12-31	Abgenix Inc.,	Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60332957D1 (de)	2002-12-16	2010-07-22	Genentech Inc	Immunoglobulinvarianten und deren verwendungen
GB0230203D0 (en)	2002-12-27	2003-02-05	Domantis Ltd	Fc fusion
AU2004205631A1 (en)	2003-01-16	2004-08-05	Genentech, Inc.	Synthetic antibody phage libraries
BRPI0407446A (pt)	2003-02-13	2006-01-31	Pharmacia Corp	Anticorpos para c-met para o tratamento de cânceres
US7220410B2 (en)	2003-04-18	2007-05-22	Galaxy Biotech, Llc	Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en)	2003-04-18	2004-10-21	Kim Kyung Jin	Monoclonal antibodies to hepatocyte growth factor
MXPA05012723A (es)	2003-05-30	2006-02-08	Genentech Inc	Tratamiento con anticuerpos anti-vgf.
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
HN2004000285A (es)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
US20080241884A1 (en)	2003-10-08	2008-10-02	Kenya Shitara	Fused Protein Composition
AU2004280065A1 (en)	2003-10-09	2005-04-21	Kyowa Hakko Kirin Co., Ltd.	Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
EA036531B1 (ru)	2003-11-05	2020-11-19	Роше Гликарт Аг	Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение
KR101520209B1 (ko)	2003-11-06	2015-05-13	시애틀 지네틱스, 인크.	리간드에 접합될 수 있는 모노메틸발린 화합물
JPWO2005053742A1 (ja)	2003-12-04	2007-06-28	協和醗酵工業株式会社	抗体組成物を含有する医薬
CA2548282A1 (en)	2003-12-11	2005-06-30	Genentech, Inc.	Methods and compositions for inhibiting c-met dimerization and activation
PT1718677E (pt)	2003-12-19	2012-07-18	Genentech Inc	Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
MXPA06011199A (es)	2004-03-31	2007-04-16	Genentech Inc	Anticuerpos anti-tgf-beta humanizados.
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
CA2885854C (en)	2004-04-13	2017-02-21	F. Hoffmann-La Roche Ag	Anti-p-selectin antibodies
SI1773885T1 (sl)	2004-08-05	2010-08-31	Genentech Inc	Humanizirani anti-CMET antagonisti
TWI380996B (zh)	2004-09-17	2013-01-01	Hoffmann La Roche	抗ｏｘ４０ｌ抗體
EP1791565B1 (en)	2004-09-23	2016-04-20	Genentech, Inc.	Cysteine engineered antibodies and conjugates
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
US20060216288A1 (en)	2005-03-22	2006-09-28	Amgen Inc	Combinations for the treatment of cancer
JP2008535821A (ja)	2005-03-25	2008-09-04	ジェネンテック・インコーポレーテッド	過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物
WO2006104912A2 (en)	2005-03-25	2006-10-05	Genentech, Inc.	C-met mutations in lung cancer
TW200732350A (en)	2005-10-21	2007-09-01	Amgen Inc	Methods for generating monovalent IgG
ES2577292T3 (es)	2005-11-07	2016-07-14	Genentech, Inc.	Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973576B1 (en)	2005-11-28	2019-05-15	Genmab A/S	Recombinant monovalent antibodies and methods for production thereof
JPWO2007063816A1 (ja)	2005-11-30	2009-05-07	東レ株式会社	ガラスペーストおよびそれを用いたディスプレイの製造方法、ならびにディスプレイ
US20070237764A1 (en)	2005-12-02	2007-10-11	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
AU2006323025B2 (en)	2005-12-05	2012-07-05	Pfizer Products Inc.	Polymorphs of a c-Met/HGFR inhibitor
JP5372737B2 (ja)	2006-03-13	2013-12-18	オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー	Ｅｇｆｒキナーゼ阻害剤およびｅｇｆｒキナーゼ阻害剤の効果に対し腫瘍細胞を感作する薬剤を用いる併用治療
CA2651567A1 (en)	2006-05-09	2007-11-22	Genentech, Inc.	Binding polypeptides with optimized scaffolds
EP2471816A1 (en)	2006-08-30	2012-07-04	Genentech, Inc.	Multispecific antibodies
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	液晶显示面板驱动装置及其驱动方法
WO2008145137A2 (en)	2007-05-31	2008-12-04	Genmab A/S	Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
WO2008145138A1 (en)	2007-05-31	2008-12-04	Genmab A/S	Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering
CA2692165A1 (en)	2007-06-25	2008-12-31	Amgen Inc.	Compositions of specific binding agents to hepatocyte growth factor
EP2014681A1 (en) *	2007-07-12	2009-01-14	Pierre Fabre Medicament	Novel antibodies inhibiting c-met dimerization, and uses thereof
PT2235064E (pt)	2008-01-07	2016-03-01	Amgen Inc	Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
US20090226443A1 (en)	2008-03-06	2009-09-10	Genentech, Inc.	Combination therapy with c-met and egfr antagonists
TW200942552A (en)	2008-03-06	2009-10-16	Genentech Inc	Combination therapy with c-Met and HER antagonists
EP2143441A1 (en) *	2008-07-08	2010-01-13	Pierre Fabre Medicament	Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
GB0812641D0 (en)	2008-07-10	2008-08-20	Prosidion Ltd	Compounds
SG10201408229WA (en)	2010-08-31	2015-02-27	Genentech Inc	Biomarkers and methods of treatment
WO2013003680A1 (en)	2011-06-30	2013-01-03	Genentech, Inc.	Anti-c-met antibody formulations
BR112014012005A2 (pt)	2011-11-21	2017-12-19	Genentech Inc	composições, métodos, formulação farmacêutica e artigo

2012
- 2012-06-29 WO PCT/US2012/044829 patent/WO2013003680A1/en active Application Filing
- 2012-06-29 SG SG2013083985A patent/SG194932A1/en unknown
- 2012-06-29 BR BR112013030472A patent/BR112013030472A2/pt not_active IP Right Cessation
- 2012-06-29 CN CN201280035071.4A patent/CN103781493A/zh active Pending
- 2012-06-29 CN CN201610902236.3A patent/CN107090038A/zh active Pending
- 2012-06-29 JP JP2014519125A patent/JP2014522843A/ja active Pending
- 2012-06-29 CA CA2835242A patent/CA2835242A1/en not_active Abandoned
- 2012-06-29 EP EP12735395.1A patent/EP2726098A1/en not_active Ceased
- 2012-06-29 TW TW101123655A patent/TW201306866A/zh unknown
- 2012-06-29 US US13/538,901 patent/US20130004484A1/en not_active Abandoned
- 2012-06-29 AR ARP120102364A patent/AR086823A1/es unknown
- 2012-06-29 KR KR1020137034360A patent/KR20140045440A/ko not_active Application Discontinuation
- 2012-06-29 RU RU2013155695/10A patent/RU2013155695A/ru not_active Application Discontinuation
- 2012-06-29 MX MX2013014687A patent/MX2013014687A/es unknown
- 2012-06-29 AU AU2012275233A patent/AU2012275233A1/en not_active Abandoned
2013
- 2013-11-04 IL IL229233A patent/IL229233A0/en unknown
2014
- 2014-11-05 US US14/534,085 patent/US9487589B2/en not_active Expired - Fee Related

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010045345A2 (en) *	2008-10-17	2010-04-22	Genentech, Inc.	Treatment method
US20110287003A1 (en) *	2010-05-14	2011-11-24	Genentech, Inc.	Treatment methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Daugherty & Mrsny, Adv Drug Del Rev. 2006; 58:686-706 *
Kerwin BA, J. Pharm. Sci. 2008; 97(8): 2924-35 *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10227416B2 (en)	2009-11-05	2019-03-12	Genentech, Inc.	Methods and composition for secretion of heterologous polypeptides
US20130078232A1 (en) *	2010-03-22	2013-03-28	Genentech, Inc.	Compositions and methods useful for stabilizing protein-containing formulations
US9662395B2 (en) *	2010-03-22	2017-05-30	Genentech, Inc.	Compositions and methods useful for stabilizing protein-containing formulations
US9487589B2 (en)	2011-06-30	2016-11-08	Genentech, Inc.	Anti-c-met-antibody formulations
US10869909B2 (en)	2012-03-27	2020-12-22	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US10195250B2 (en)	2012-03-27	2019-02-05	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US20150258194A1 (en) *	2012-08-31	2015-09-17	Vib Vzw	Modulating transendothelial migration and recruitment of granulocytes by modulating c-met pathway
US10610568B2 (en)	2013-01-30	2020-04-07	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US9827291B2 (en)	2013-01-30	2017-11-28	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US9828415B2 (en)	2013-01-30	2017-11-28	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US10323075B2 (en)	2013-01-30	2019-06-18	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US9517266B2 (en)	2013-03-29	2016-12-13	Samsung Electronics Co., Ltd.	Liquid formulation containing a protein drug
JP2016534062A (ja) *	2013-10-25	2016-11-04	バイエルファーマアクチエンゲゼルシャフト	新規な安定製剤
US10240207B2 (en)	2014-03-24	2019-03-26	Genentech, Inc.	Cancer treatment with c-met antagonists and correlation of the latter with HGF expression
US11358995B2 (en)	2014-07-30	2022-06-14	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US9834586B2 (en)	2014-07-30	2017-12-05	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US11530260B2 (en)	2014-10-31	2022-12-20	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US9920118B2 (en)	2014-10-31	2018-03-20	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US10562965B2 (en)	2014-10-31	2020-02-18	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
AU2015342815B2 (en) *	2014-11-07	2018-12-13	Novartis Ag	Stable protein solution formulation containing high concentration of an anti-VEGF antibody
AU2018274882B2 (en) *	2014-11-07	2020-07-09	Novartis Ag	Stable protein solution formulation containing high concentration of an anti-VEGF antibody
US10689438B2 (en)	2014-11-07	2020-06-23	Novartis Ag	Stable protein solution formulation containing high concentration of an anti-VEGF antibody
IL280087A (en) *	2014-11-07	2021-03-01	Novartis Ag	Stable formulations of protein solutions containing high concentrations of anti-vegf antibody
WO2016073915A1 (en) *	2014-11-07	2016-05-12	Novartis Ag	Stable protein solution formulation containing high concentration of an anti-vegf antibody
AU2020244614B2 (en) *	2014-11-07	2023-06-01	Novartis Ag	Stable protein solution formulation containing high concentration of an anti-VEGF antibody
US11884734B2 (en)	2015-03-16	2024-01-30	Celldex Therapeutics, Inc.	Anti-MET antibodies and methods of use thereof
TWI735486B (zh) *	2015-12-10	2021-08-11	日商新力股份有限公司	收訊裝置、及資料處理方法
US10975154B2 (en)	2016-03-31	2021-04-13	Ngm Biopharmaceuticals, Inc.	Binding proteins and methods of use thereof
US10174119B2 (en)	2016-03-31	2019-01-08	Ngm Biopharmaceuticals, Inc.	Binding proteins and methods of use thereof
US11945859B2 (en)	2018-12-18	2024-04-02	Novartis Ag	Protein solution formulation containing high concentration of an anti-VEGF antibody
US11634485B2 (en)	2019-02-18	2023-04-25	Eli Lilly And Company	Therapeutic antibody formulation

Also Published As

Publication number	Publication date
US20150064191A1 (en)	2015-03-05
JP2014522843A (ja)	2014-09-08
RU2013155695A (ru)	2015-08-10
AU2012275233A1 (en)	2013-11-28
CN103781493A (zh)	2014-05-07
KR20140045440A (ko)	2014-04-16
US9487589B2 (en)	2016-11-08
IL229233A0 (en)	2014-01-30
BR112013030472A2 (pt)	2019-09-24
AR086823A1 (es)	2014-01-22
WO2013003680A1 (en)	2013-01-03
CN107090038A (zh)	2017-08-25
TW201306866A (zh)	2013-02-16
WO2013003680A8 (en)	2013-02-28
MX2013014687A (es)	2014-02-17
EP2726098A1 (en)	2014-05-07
SG194932A1 (en)	2013-12-30
CA2835242A1 (en)	2013-01-03

Legal Events

Date

Code

Title

Description

2012-08-30

AS

Assignment

Owner name: GENENTECH, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEMEULE, BARTHELEMY;KABAKOFF, BRUCE;LIN, JUN;AND OTHERS;SIGNING DATES FROM 20120718 TO 20120829;REEL/FRAME:028876/0461

2012-10-04

AS